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ABSTRACT 
 
During the last decades, the technological evolution has been very fast 
and has paved the way to a wide set of theoretical approaches able to support 
and stimulate the experimental component of biological sciences. From this 
standpoint, in drug discovery and design, the ability to make working hypothesis 
on how a small molecule interacts with its biological target can lead to rational 
approaches for the developing of new drug candidates.  
Nowadays is possible to model the behaviour of chemical systems up to 
the atomistic scale, allowing retrieve insights on mechanisms behinds the ligand 
binding and unbinding from a receptor. Among the computational techniques 
available, molecular dynamics is able to take in account fundamental aspects 
linked to the time evolution of a biological system, such as structural flexibility 
and the dynamic role of water molecules in the protein binding sites. 
During this Ph.D. project we employed molecular dynamics in order to 
disclose putative binding mechanisms of several ligands: more precisely, we 
applied the supervised molecular dynamics (SuMD) technique to decipher the 
binding pathways of both allosteric modulators and agonists to the adenosine 
receptors subtypes (belonging to class A of G protein-coupled receptors). 
Interestingly, findings highlights the coexistence of different potential 
recognition pathways that anticipate the formation of the orthosteric 
intermolecular complexes, as well as the crucial role of residues located at the 
extracellular portion of the protein. 
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SOMMARIO 
 
Nel corso degli ultimi decenni, l'evoluzione tecnologica è stata così rapida 
da aprire la strada a una vasta gamma di approcci teorici in grado di supportare e 
stimolare la componente sperimentale delle scienze biologiche. Da questo punto 
di vista, in drug design, la capacità di fornire ipotesi di lavoro su come una 
piccola molecola interagisce con il suo bersaglio biologico può portare ad 
approcci razionali per lo sviluppo di nuovi candidati farmaci.  
Oggigiorno è possibile modellare il comportamento di sistemi chimici 
fino alla scala atomica, consentendo di avere informazioni sul meccanismo che 
guida associazione e dissociazione da un recettore. Tra le tecniche di calcolo 
disponibili, la dinamica molecolare è in grado di prendere in considerazione 
fondamentali aspetti legati all’evoluzione temporale di un sistema biologico, quali 
la flessibilità strutturale e il ruolo dinamico delle molecole d'acqua nei siti di 
legame proteici. 
Durante questo progetto di dottorato di ricerca abbiamo impiegato la 
dinamica molecolare al fine di rivelare i possibili meccanismi di riconoscimento 
di diversi ligandi, soprattutto nei confronti dei sottotipi recettoriali dell'adenosina 
(appartenenti alla classe A dei recettori accoppiati a proteine G): più 
precisamente, abbiamo applicato tecniche di dinamica molecolare supervisionata 
(SuMD) sia a modulatori allosterici che ad agonisti. È interessante notare che i 
risultati evidenziano la co-esistenza di diversi possibili meccanismi di 
riconoscimento, che anticipano la formazione dei complessi intermolecolari 
ortosterici, oltre ad il ruolo cruciale di residui localizzati nella porzione proteica 
extracellulare.  
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1.1 BINDING AND UNBINDING: AN  OVERVIEW 
 
Binding between organic molecules has ever been the motor of life since 
its outset1. Inside biological systems, intermolecular recognitions often are the 
first step for transduction of the chemical signals required for physiological 
functionalities: gene regulation2, hormonal signal cascades3 and enzymatic 
metabolism4 are just a few examples of biological events, subjected to binding 
with endogenous or exogenous chemicals. Likewise for all the natural 
phenomena, thermodynamics laws are able to explain and describe the physics 
and the driving forces that stand behind the formation of intermolecular 
complexes, as well as the kinetics behaviour of the entire binding and unbinding 
phenomena.  
In this first section some fundamental aspects of binding, both from 
kinetics and thermodynamics point of view are shortly introduced to the reader, 
then the main forces that drive and influence binding are briefly elucidated. 
 
 
1.1.1 BINDING THERMODYNAMICS AND KINETICS: TWO 
 FACES OF THE SAME COIN 
 
Is difficult to divide the binding thermodynamics characterization 
(quantified by the equilibrium association constant KA and the dissociation 
constant KD) from its kinetic description (reflected by the rate constants kon and 
koff). Considering a single step mechanism, at the steady state the ligand (L) and 
its receptor (R) form an intermolecular complex according to the law of mass 
action: 
 
L + R ⇄ LR    (1) 
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The dynamic proprieties of the equilibrium allow to relate the 
thermodynamics dissociation constant KD (which in turn is the reciprocal of KA) 
to the binding kinetics rate constants kon and koff  (equation 2): 
 
   (2) 
 
The recognition event, which depends on the concentration of both 
ligand and receptor, is a second order reaction (kon is expressed in M-1s-1), while 
the dissociation is function only of the intermolecular complex concentration 
(koff is measured in unit of s-1). This important difference is caused by the 
intrinsic two steps nature of intermolecular recognition5: indeed, while the 
dissociation take place in one stride regulated only by the interactions between 
ligand and receptor, the association can be distinguished in two different phases. 
During the first stage (before any interaction occurs) the ligand diffuses through 
the media and the probability of a productive collision with the protein rely on 
its own concentration (we can assume a kinetics rate constant kdiff for this step, 
measured in M-1). Upon the first interactions with the receptor are established, 
recognition no more relies on concentration but only on the binding mechanism 
and its energetic progress, leading to measure a proper interaction kinetics rate 
constant (namely kint) in unit of s-1. It follows that the total binding kinetics rate 
kon can be considered the combination of the two phases (equation 3): 
 
kon = kdiff · kint    (3) 
 
Generally, for a drug−like compound, kinetics kon value is in the range of 
103 M-1s-1−109 M-1s-1 (the latter is about the rate limit of free diffusion in 
solution), while the koff can spread from around 10-7 s-1 to approximately 1 s-1 and 
usually is the main contributor to the KD value6 as expressed in equation 2. 
Interestingly, super−fast binders (characterized by kon values higher than 109 M-1 
s-1) have been evolutionary selected as effectors of physiologic processes that 
KD =
[L][R]
[LR] =
koff
kon
= KA−1
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need instant regulation, like in the case of acetylcholine on the enzyme 
acetylcholinesterase (AChE)7 in the central nervous system (CNS). 
During the last decade, an increasing attention has been addressed to the 
kinetics concept of residence time (tr), first introduced in 2006 8 and defined as 
the reciprocal of the koff  value (so is expressed in unity of seconds):  
 
   (4) 
 
According to experimental evidences, tr is related to the in vivo biological 
effects triggered by the ligand6,9. Usually, a high tr value is considered useful for 
the pharmacodynamics profile, especially if it is longer than the 
pharmacokinetics elimination lifetime, otherwise is the mass−balance effect, 
drove by elevated local drug concentrations, to sustain the effect of the drug10 
(Figure 1). Nevertheless, also adverse effects can be linked to tr, both off−target 
and target mediated11.  
 
 
Figure 1. Plot showing the ratio between plasma half-lives and dissociation half-lives on 
a logarithmic scale (y axis) for some commercialized drugs. Dissociation half-lives is 
defined as Dt1/2 =
ln2
koff
 .(Adapted from ref. 10). 
tr =
1
koff
  
6 	   INTRODUCTION	   	  
	   	  
6 
On the other hand, the kon has a crucial role in protocols for binding 
measurements12: indeed, the kinetics on−rate of ligands involved in the 
experimental procedures drive the timing needed for the achievement of 
equilibrium conditions. 
The free energy profile that characterizes binding and unbinding events is 
usually modelled as reported in Figure 2. According to the transition state theory 
(TST)13, the highest point on the pathway (LR‡) represents the transition state 
between the unbound (L + R) and the bound configuration (LR). As stated in 
Eyring’s equation (equation 4), the kinetics constants (kon/off) are proportional to 
the exponential of the energies of activation of the respective transition states 
(ΔG‡on/off), through a pre-exponential factor that combines the Boltzmann’s 
constant kB, the Planck’s constant h and the absolute temperature T:  
 
    (4) 
 
Thermodynamics constants KD and KA, instead, are related to the ΔGbinding, 
according to the equation 5: 
 
KD = e
ΔGbinding
RT = KA−1     (5) 
 
Eyring’s theory is the elegant combination of different thermodynamics, 
statistics and kinetics mathematical approaches developed until 193514. Its power 
resides in its versatility, as is able to describe the kinetics behaviour of almost all 
the chemical systems. What allows us to apply this model (in principle developed 
for chemical reaction and two body interacting systems) to complex systems (as 
a fully solvated protein−ligand complexes can be considered) is that, along a 
single path, the dynamics of the transition depends only on the slowest steps 
involved (the one associated to the highest energy). Importantly, this assumption 
does not imply that the binding or unbinding kinetics are defined by only one 
Kon/off =
kBT
h e
−
ΔG±on/off
RT
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transition state, but more realistically, different pathways (therefore different 
transition states) can contribute with different weights to the observable kon and 
koff values. 
 
 
 
Figure 2. Simplified binding and unbinding energy profile. The highest energy point 
(LR‡) is the transition state between the unbound (L + R) and the bound state (LR). 
The energy difference between the two states is ΔGbinding, while ΔGon and ΔGoff 
quantifies the energy variation between LR‡ and the two energy basins. 
 
Considering one of these possible energetic pathways (Figure 2), the 
definition of the reaction coordinate able to describe the free energy profile 
during the systems’ transition become tricky, passing from a two body 
interacting system (which evolution is well depicted by the distance between the 
components of the system) to a biological system, where transitions may be 
better outlined by multiple descriptors15–17 (e.g the combination of 
intermolecular distances, dihedral torsional angles, degree of solvation, angles 
formed by different centres of mass etc etc). To complicate the picture, there is 
the difficulty to determine which step, among all in the transition pathway, may 
represent the limiting one, or if two or more transition states are energetically 
degenerate, therefore equally contribute to the overall kinetics. In Figure 3, as an 
example, is reported the comparison between two reaction coordinates (runi and 
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ropt) monitored during the molecular dynamics simulation of a 47−residues 
protein16: the distribution of the conformations follows a bimodal trend (Figure 
3, panel B and E), which is better described by the reaction coordinate ropt, able, 
indeed, to avoid overlaps (Figure 3, panel B) and to highlight the protein 
conformation associated to the transition state (the conformation associated to 
the lower probability). 
 
 
Figure 3. Comparison between reaction coordinates. (A and D) Reaction coordinates 
values during the same molecular dynamics simulation; (B and E) distribution 
probability of the two reaction coordinates; (C and F) the probability of being on a 
transition path. The green horizontal lines indicate transition states. (Adapted from ref 
16). 
 
Ligand binding and unbinding events are multi steps processes, usually 
characterized by stable states that anticipate the final bound (or fully solvated 
unbound in the case oh unbinding) configuration18–21 as depicted in Figure 4 for 
the case of alprenolol on the β2 adrenoreceptor (β2 AR)20.  
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Figure 4. Alprenolol–β2 AR binding metastable states. Pins indicate successive positions 
of alprenolol (A); the molecules moves from bulk (1), to the extracellular vestibule (2 
and 3), and finally into the binding pocket (4 and 5). (Adapted from ref 20). 
 
From this standpoint, if we consider a two steps ligand−receptor 
recognition (or dissociation) event (equation 6), the formation of a metastable 
intermediate complex LR*M has to be considered thermodynamically and 
kinetically related to the unbound state (L + R) and the final bound state (LRB): 
 
L + R ⇄ LR*M ⇄  LRB   (6) 
 
Again, the free energy profile can be simplified as reported in Figure 5. In 
this model the formation of an initial drug–receptor intermediate complex 
(LR*M) anticipate the slower (because of the highest energy barrier ΔG‡B) 
formation of the final bound state (LRB). In this case, compared to the single 
step binding model (equation 2), the definition of the thermodynamics 
dissociation constant KD can be computed through a more complicate 
combination of the kinetics constants from each step (equation 7)22,23: 
 
    (7) 
 
KD =
k2
k1 +
k1 + k1k3
k4
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Figure 5. Energy profile of a two steps binding mechanism, characterized by a slower 
second step. Between the unbound state L + R and the bound state LRB the system 
experiences a stable intermediate complex LR*M. The kinetics is governed by four 
constants (k1, k2, k3 and k4), while the thermodynamics is determined by the ΔGbinding 
value. 
 
At the steady state, ΔGbinding can be quantified as the variation, from the 
initial unbound to the final bound state (and vice versa in the case of unbinding), 
of two state functions of the system: enthalpy (H) and entropy (S) (equation 8): 
 
ΔGbinding =Gbound −Gunbound = ΔHbinding −TΔSbinding   (8) 
 
A negative ΔHbinding value is considered favourable for binding24 and 
reflects a positive change in the number and/or strength of intermolecular 
interactions. In the same way, a negative value for -TΔSbinding indicates an 
increase in entropy, ascribable to favourable changes24 in translational, rotational 
or conformational entropy of the system. Studies carried out on sets of different 
intermolecular complexes highlighted the general tendency of enthalpy−entropy 
compensation: ligand binding appears to be energetically driven by either a 
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favourable enthalpy variation or a favourable entropy variation, but usually not 
by a concordant effect of the two24,25.  
An alternative point of view on binding and unbinding is offered by 
statistical mechanics26,27. According to this treatise, in equilibrium conditions, a 
system can be described as the sum of the energy of all its possible microstates, 
each one associated to a probability to exist quantified from its own energy. As a 
consequence, microstates with low energy are more populated and, if we label 
the ith microstate by its energy Ei, the probability of a specific microstate is given 
by equation 9: 
 
     (9) 
 
where -βEi is called the Boltzmann factor (β = 1/KBT ) and Z is the partition 
function, defined as the sum of all the possible microstates. Intuitively, the 
probability associated to a ligand–receptor bound configuration increase 
exponentially with the energy of stabilization generated by the intermolecular 
complex formation.  
 
pi =
1
Z e
−βEi
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1.1.2 BINDING DRIVING FORCES 
 
During an intermolecular recognition, different events occur and in a 
general view, both the ligand and the receptor respectively: i) partially desolvate; 
ii) rotationally rearrange, in order to reach the right conformation for recognition 
and iii) establish new interactions. Each step needs a certain amount of energy 
for its activation and can be more related to a change in enthalpy or in entropy. 
 
1.1.2.1 Intermolecular interactions 
 
Like protein–protein association28, also the recognition of small 
molecules is strongly affected by electrostatics interactions. In physiological pH 
conditions, molecules can be in ionized if their chemical structure includes basic 
or acidic functional groups, and when two charges of opposite signs establish a 
favourable ionic interaction, the enthalpy of the stabilization is determined by:  i) 
the charge densities present on the respective atoms; ii) the interatomic distance 
and iii) the dielectric constant ε of the microenvironment. Notably, charges 
located at the protein surface may experience a different dielectric constant than 
charges buried in the protein core, with ε values that can diverge from ≈20-80 (at 
the bulk solvent interface) to ≈ 1-4 (inside buried protein cavities)29,30. During a 
salt bridge formation, the total free energy change ΔGtot can be generalized as 
the algebraic sum of different terms31 (equation 10): 
 
ΔGtot = ΔGdslv + ΔGbrd + ΔGprt + ΔGrot   (10) 
 
More precisely, ΔGdslv takes in account the desolvation penalties that 
individual charged atoms have to overcome in their passage from the water to 
the protein environment; ii) ΔGbrd is the favourable enthalpy due to the 
interaction of oppositely charged functional groups; iii) ΔGprt represents the 
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change in interactions between the new formed salt–bridge and the rest of the 
protein. Moreover, especially if long side chain amino acid residues are involved 
(as lysine or arginine), a loss of rotational entropy ΔGrot should be considered for 
the overall ΔGtot. 
Moving to other classes of intermolecular interactions, hydrogen bonding 
probably represents the most common polar interaction in nature, being the 
intermolecular force characterizing the main constituent of the biosphere: the 
water. From a molecular point of view, at small separation distances between 
atoms involved, hydrogen bonds are governed by a balance between attractive 
and repulsive electrostatics, charge transfers and polarizations phenomena, while, 
at larger distances, are almost completely electrostatics32. In pure water, the 
strength of an hydrogen bond is about 3.7 kcal/mol33, but the stability provided 
by a single interaction depends on the degree of solvent exposure34 as well as the 
nature of the heteroatoms involved and their relative positions35. Moreover, the 
formation of a hydrogen bond, beside the enthalpy stabilization, implies also a 
minor entropy loss36. Recently, an increasing attention has been addressed to the 
understanding of how hydrogen bonds influence the binding and unbinding 
kinetics: hydrogen bonds buried inside protein cavities are generally shielded 
from water molecules and their rupture (and formation) are associated to 
energetically penalized transition states, as we can consider dehydration and 
rehydration occurring asynchronously37 (Figure 6). This scenario is well 
exemplified by the biotin–streptavidin complex, where the water entrance in the 
binding pocket (Figure 7) during the unbinding is highly unfavourable due to the 
presence of a net of hidden hydrogen bonds38,39. 
Despite huge efforts made by the scientific community, there is still lack 
of a univocal model able to describe the contribution to intermolecular 
recognition40 generated by hydrophobic interactions. From a computational 
point of view, hydrophobic interactions are estimated through the Lennard–
Jones potential41 or on the basis of the surfaces involved: the stabilization 
generated is generally quantified in the range of 25–75 cal/Å242. Unsaturated 
rings have been extensively reviewed43 and in a recent study44 Pi-Pi stacking 
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interactions, have been compared with hydrophobic interactions involving sp3 
carbon atoms rings: interestingly, has emerged that in drug-like molecules the 
replacement of phenyl groups with saturated rings seems not to negatively affect 
the affinity. 
 
 
Figure 6. Representation of the hydrogen bond exchange processes between water and 
ligand (a) with a solvent-exposed polar atom; (b) for an almost buried polar atom; (c) 
with a solvent-exposed polar atom with a bulkier ligand. (Adapted from ref 37). 
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Figure 7. Biotin binding site location in the crystal structure of streptavidin. (Adapted 
from 38). 
1.1.2.2 Role of water molecules 
 
Since the dawning of modern sciences, water has been considered a 
cornerstone of biological processes, because of its fundamental impact in protein 
plasticity, protein–protein interactions and small molecules’ binding45. 
Nowadays, the role of water during ligand association and dissociation 
represents a challenging field for medicinal chemists46, mainly due to the 
dichotomy between enthalpy and the entropy, which in water molecules 
probably finds its maximum expression within biological systems47,48. As a rule 
of thumb, water molecules in binding sites are partially restrained by irregular 
shapes of the protein surface. Moreover, cavities are frequently hydrophobic 
environments, whose solvation requires an energetic cost that can be regained 
thanks to the replacement of unfavourable water molecules with lipophilic 
moieties belonging to bound ligands49–51. From this point of view, the so-called 
“magic methyl effect”52,53 is probably the most famous manifestation, in 
medicinal chemistry, of the effect mediated by the displacement of instable water 
molecules from the receptor surface during the binding. The analysis of several 
thousands crystal structures revealed that at least a water molecules mediates 
contacts between protein and ligand in almost two–thirds of all complex 
considered54,55. As demonstrated by the rational design of non-peptide HIV 
protease inhibitors56, medicinal chemists have to take in account water and its 
importance in intermolecular recognition57. A number of different 
computational methods have been developed with the aim of predict the 
presence of water molecules in protein–ligand complexes58, including Grand 
Canonical Monte Carlo (GCMC)59 and WaterDock60. In general, MD–based 
techniques show relevant potentiality for this application, allowing to quantify 
the energetic contribution produced by water mediated interactions61, or to 
evaluate the water accessibility to binding sites during unbinding events62. One 
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of these methods is WaterMap63: it consists of an all-atom MD simulation 
carried out in explicit solvent. Output trajectory thermodynamics is statistically–
analysed to define potential hydration sites according to water clusters detected. 
WaterMap drove the development of a series of platelet-derived growth factor 
receptor β (PDGFR-β) inhibitors, thanks to the design of a structural 
modification of the ligands able to target a weakly bound water molecules, 
leading to a 25-fold improvement in IC5064 (Figure 8).  
Interestingly, by means of long classic MD simulations, water molecules 
have been indicated as responsible for early kinetic barrier during ligand 
approach to G-protein coupled receptors (GPCRs), due to the dehydration that 
takes place as the drug associates with the extracellular vestibule of the 
receptors20,65. 
 
 
Figure 8. Development of PDGFR-β inhibitors using WatertMap. The replacement of 
an indole group is able to displace an unfavourable water molecule (in red) and improve 
the overall interactions through a water bridge molecule (in green). (Adapted from 58). 
 
 
1.1.2.3 Conformational changes  
 
Almost thirty years ago a new concept was introduced in the field of 
protein biophysics66,67, the energy landscape, which is the free energy associated 
to all the possible protein conformations. Each protein conformation is, in turn, 
a function of all the degree of freedom (mainly dihedral angles of the backbone). 
In this representation, valleys are stable and favourable conformations the 
protein can explore with kinetics and probabilities that depends on the shape of 
the surface that separate two or more minimum. This scenario suggests the 
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existence of an ensemble of possible pathways, intermediate states and transition 
states connecting two stable points.  
In physiological conditions, the presence of a ligand in the surrounding 
environment of a protein can produce a shift in the protein conformational 
distribution68. Generally, two models of binding mechanism are considered 
(Figure 9): a) the “conformational selection” (equation 9), where the ligand L 
only binds one of the macromolecule conformational states R’,R’’,R’’’ (usually 
presents only in small amounts) and b) the “induced fit” mechanism (equation 
10), characterized by the ligand binding to the predominant protein 
conformation, followed by an isomerization of the complex (RL*) to yield the 
final form (RL): 
 
〈R’,R’’,R’’’,…〉 + L ⇄ LR     (9) 
  
R + L ⇄  RL* ⇄  RL    (10) 
 
Even if is well established that the mechanistic model followed is 
influenced by the protein and ligand concentrations, it has been proposed a 
major role for the conformational selection69–71.Considering the induced fit 
model, both the first and the second step can involve a conformational change 
of the target and/or the ligand, with a relative kinetics usually slower if is the 
target to experience a conformational isomerization, due to the higher number 
of degree of freedom implied72. This high number of degrees of freedom and the 
complexity of the free energy surface make difficult to estimate its overall 
thermodynamic influence on binding, especially for the entropic component73.  
Ligand and protein side chains conformational changes, instead, are 
linked to the exploration of a relatively low number of rotatable bonds and, 
therefore, are more easily addressable using a range of both experimental and 
computational techniques 74–76. Notably, can exist a substantial difference 
between the more stable ligand conformations in the bulk solvent and the 
binding conformation77,78 (bioactive in the case of an agonist) and it is important 
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to note that binding brings an unfavourable entropy contribution to the total 
free energy 79,80. 
 
Figure 9. Comparison between conformational selection (a), where the ligand 
selectively binds a single conformation (stabilizing it) and induced fit (b), where the 
ligand induces conformational rearrangements in the macromolecule to optimize the 
interaction. (Adapted from ref 69). 
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1.2 MOLECULAR DYNAMICS AS A POWERFUL TOOL FOR 
 INVESTIGATE BINDING AND UNBINDING EVENTS 
 
Structure based drug design (SBDD) has its roots in the middle of the last 
century, when the first pioneering results were obtained from X-ray 
crystallography techniques81. During the following decades the possibility to 
investigate biological macromolecules at atomistic resolution, as well as the 
constantly increasing computational performances, paved the way to molecular 
simulations in the pharmaceutical field. Docking simulations82 rapidly became a 
fundamental tool in drug discovery, due to the opportunity of efficiently 
perform virtual screenings of vast virtual libraries of compounds and rationalise 
the structure-activity relationship (SAR) able to drive the optimization of hit and 
lead compounds. Main purpose of docking is to explore possible ligands’ 
conformations in their binding site, semi-quantitatively evaluating the stability of 
intermolecular complexes generated on the basis of shape and electrostatics 
complementarity.  
More recently, other force field–based techniques have been developed: 
alchemical perturbation (AP) methods83 and molecular mechanics energies 
combined with the Poisson-Boltzmann or generalized Born and surface area 
continuum solvation (MM/PBSA and MM/PBSA) represent common tools for 
evaluate ligand binding affinities84. These approaches, whose results strongly 
depend on the chemical system considered, take advantage of short molecular 
dynamics (MD) simulations performed on both ligand and receptor 
conformations extracted from docking, quantifying the energetic stability of a 
binding mode and neglecting how the binder should reach the putative bound 
configuration.  
In the last years increasing efforts have been addressed to decipher the 
ligand-receptor binding phenomena at an atomistic scale, with the aim of 
characterize the driving forces that move a small molecule from the solvated 
unbound state toward the stable final intermolecular complex, and vice versa. 
From this standpoint, MD is a promising tool, able to take in account protein 
  
20 	   INTRODUCTION	   	  
	   	  
20 
and ligand flexibility as well as the dynamic role of water molecules. Disclosure 
of a more detailed picture about binding mechanisms may allow the 
development of alternative and innovative drug discovery strategies, able to 
bridge the chemical modification introduced with the experimentally–determined 
kinetics. In this scenario, beside the structure-activity relationship (SAR) 
approach, the structure–kinetic relationship (SKR) is constantly gaining 
popularity85. The introduction of the time as a variable in computational 
simulations allow consider the systems’ evolution according to how their 
components can dynamically and reciprocally interact: starting from an initial 
configuration on the energy landscape is possible to sample possible evolutions 
and pathways from a local minimum to another, passing through saddle points. 
In other words, by means of classic MD, which nowadays is already able to reach 
the millisecond time scale86,87 thanks to the recent introduction of the graphic 
processing unit (GPU) technology and dedicated MD codes, is possible to 
reconstruct the ligand transition from the unbound state to the bound 
intermolecular complex, which represents a minimum of the system energy 
landscape. From this point of view, a crucial task is to sampling ligand binding or 
unbinding events an adequate number of times, as any observable retrieved from 
MD (e.g. energy values or kinetics rate) should derive from a statistical approach 
(and may consider the systematic error introduced by using rude molecular 
mechanics force fields).  
On the other hand, the dissociation of a intermolecular complex can not 
be simulated using a classic MD approach, because of the high energy barrier of 
the transition state associated, that impose timescales still unreachable for the 
methodology. Indeed, in order to sample possible unbinding pathways and 
mechanisms, the so-called “enhanced sampling” methods are employed.  
This section introduces the applicability of classic MD to the study of 
binding events as well as some enhanced methods that have been successfully 
used to characterize unbinding mechanisms. 
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1.2.1  CLASSIC MOLECULAR DYNAMICS FOR THE 
MODELING OF BINDING EVENTS 
 
In drug design, classic MD is often combined with molecular docking 
methods with the aim of evaluate the quality of docking solutions as well as to 
their refinement and tuning88,89. However, classic MD represents a powerful 
method for disclosing the entire mechanisms of binding and has gained 
increasing visibility in the last years: in 2011 Buch et al. reconstructed for the first 
time at atomistic detail a ligand–protein recognition event18, retrieving kinetic 
and thermodynamics parameters in good accordance with experimental data. A 
pioneering study in the G protein-coupled receptors (GPCRs) field is 
represented by the work of Dror et al.20. The authors performed classic MD 
simulations on both the β2 adrenergic receptor (β2 AR) and the β1 adrenergic 
receptor (β1 AR): interestingly, the antagonist alprenolol bound to β2 AR 
exploring a predominant pathway, characterized by different metastable sites 
located between extracellular loop 2 (EL2) and 3 (ECL3). Decherchi et al.90, 
instead, combined classic MD simulations with machine learning algorithms in 
order to reconstruct the binding of an inhibitor to the purine nucleoside 
phosphorylase enzyme. After microseconds of simulation, a final intermolecular 
complex in agreement with the experimentally determined one was gained, 
highlighting three different main binding pathways to the active site and 
therefore corroborating the experimental slow kinetics measured.  
Usually, the concept of binding is associated to the initial ligand diffusion 
from the bulk solvent to the receptor surface, however it is important to 
consider that about 60% of drugs targets are located at the cell surface91 and that 
membrane proteins are immersed in a peculiar environment. It follows that 
lipophilic binders may reach their recognition sites also from the lipid bilayer, as 
described by of Stanley et al.19. In this work, the binding of the inhibitor ML056 
to the sphingosine-1-phosphate receptor 1 (S1P1R) was reconstructed using 
classic MD simulations and Markov state models (MSMs)92: the aggregate 
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sampling time of over 800 µs allowed to highlight four different stages during 
the binding pathway.  
MSMs92 are a powerful statistical approach recently introduced for the 
computation of kinetics parameters from MD simulation. Briefly, assumed that 
short simulations allow observe system transitions between states that are 
kinetically near, a number of short parallel MD simulations are performed 
starting from different initial configurations. A structural descriptor is followed 
during the simulations and when its value become stationary a new simulation is 
started with the goal of to avoid the over sampling of metastable configurations 
(therefor the quality of the data set collected is improved). After the short MD 
trajectories are collected, a set of microstates is defined performing a clustering 
based on the structural descriptor (clusters are represented by the number of 
states that are comprised) and a microstate transition matrix is constructed. 
Configurations in the MD trajectories are, one by one, compared to microstates 
to find out to which microstate they can be assigned: the result is a translation of 
the overall MD trajectory from a series of structures over time to a series of 
microstates over time93. The aim is to count how many transitions are observed 
between each pair of microstates i and j during a lag time τ in order to estimate 
their probability in that time window93. MSMs constructions have been applied 
to chemical system of increasing complexity: recently Plattner et al. reconstructed 
the binding of benzamidine to β-Trypsin94, revealing that the enzyme can exist in 
six main conformations and that the overall mechanism exhibits features of both 
induced fit and conformational selection. Gu et al., instead, employed MSMs to 
study the choline binding to the endogenous protein ChoX95, ascribing the 
recognition mainly to the conformational selection model. Kohlhoff et al.96 carried 
out a cloud-based MSM approach to simulate a total time of 2.15 ms on the β2 
adrenergic receptor (β2 AR). During this study, the authors started from both 
inactive and active crystal structures of the receptor, in presence of two different 
ligands (the partial inverse agonist carazolol and the full agonist BI-167107): 
findings revealed that binding to both of the two isomers may take place through 
multiple pathways, that comprises metastable intermediate sites. 
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Recently we have proposed an alternative unbiased MD based method 
for the characterization of possible pathways during recognition events: the 
supervised molecular dynamics97,98 (SuMD). According to this approach, the 
timescale needed to reproduce complete intermolecular complex formations 
results in the range of nanoseconds, instead of hundreds of nanoseconds or 
microseconds usually necessary with classic MD. Sampling is gained without the 
introduction of bias, but just by applying a tabu–like algorithm (Figure 10) to 
monitor the distance between the center of masses of the ligand and the binding 
site, during short classic MD simulations.  
 
 
Figure 10. SuMD algorithm scheme. The ligand–receptor distance vector (dcmL-R) is 
collected at regular time intervals and an interpolating linear function is calculated after 
each time window. 
 
During each SuMD time window, an arbitrary number of distance points 
is collected at regular time intervals and fitted into a linear function. If the slope 
of the resulting straight line is negative, the ligand-receptor distance is likely to 
be shortened and the simulation is restarted using coordinates and velocities 
from the very last SuMD production step. Otherwise, the simulation is restored 
from the set of coordinates from the last productive step, by reassigning atoms 
velocities according to Boltzmann distribution. When the ligand–binding site 
distance reaches a predetermined value, the supervision is stopped and the 
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system can freely evolve without supervision. Some recent SuMD applications 
comprise the binding reconstructions of adenosine to its endogenous receptor 
A2A99, as well as of the positive allosteric modulator (PAM) LUF6000 on the 
adenosine receptor subtype A3100. 
 
 
1.2.2  METHODS THAT INTRODUCE A SCALAR ENERGY 
BIAS IN THE SYSTEM POTENTIAL ENERGY 
 
As already stated, dissociations of intermolecular complexes require the 
overcome of high-energy barriers in order to activate the process. This, in turn, 
affect the timescale needed to observe a spontaneous unbinding, which can 
reach up to days or weeks in the case of very slow-off ligands. In order to 
facilitate the systems’ transition to the dissociate configuration, some MD–based 
approaches have specifically developed in order to modify the energy landscape. 
More precisely, the introduction of a new scalar value in the mathematical 
function that rule the potential of the system allow to flatten the energy surface 
and therefore to increase the probability to simulate kinetically–unfavourable 
events. 
Recently, the scaled MD approach101 (Figure 11), originally introduced as 
a tool for protein folding sampling, was applied to the unbinding study of seven 
modulators of the enzyme glucokinase 1 (GK1)102,103. Biasing the electrostatic 
and the Lennard-Jones potentials, the authors were able to simulate different 
ligands’ transitions from the bound complex to the unbound state and, after 
some simplifications and by using a statistical approach, compared the computed 
residence times to the experimental values. Interestingly, even if this method 
implies a loss of details of the unbinding path, findings suggested that 
compounds characterized by a T-shaped geometry exhibits a longer residence 
time, ascribed to an induced fit binding mechanism inside the linearly shaped 
recognition cavity of the enzyme. 
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Figure 11. Schematic illustration of scaled MD. (A) Different scaling values lead to 
distinct energy surfaces: the higher the scaling factor the flatterer is the surface; (B) 
changes in probability distributions for the different scaling factors. (Adapted from ref 
101). 
 
A further enhanced sampling approach is the accelerated molecular 
dynamics (AMD)104. During an AMD simulation, the system energy potential 
V*(r) changes continually, according to a function block that defines when to 
add the bias (equation 11): 
 
   (11) 
 
V(r) represents the unbiased potential energy of the system and E is a predefined 
threshold energetic parameter. It follows that potential energy landscape minima 
that lie below E are raised, therefore reducing the neighbouring energy 
barriers105. The AMD usually bias the potential associated to the dihedral energy 
of the system, as recent employed in the GPCRs field to reconstruct the binding 
to the octopamine receptor106 and the M3 muscarinic receptor107. 
The possibility to modify the temperature in the simulation inspired the 
development of the temperature replica exchange algorithm (T–REMD), first 
applied to MD simulations by Sugita et al in 1999108. During T–REMD several 
parallel simulations are performed at different temperatures and periodically 
pairs of replicas are exchanged according to a statistical criterion: the resulting 
sampling in the temperature space increases the probability to escape from local 
V *(r) = V (r)⇔V (r) ≥ EV (r)+ΔV (r)⇔V (r)< E
$
%
&
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energy minima109. Differently from T–REMD, during the Hamiltonian replica 
exchange (H–REMD) are the force field parameters to be exchanged between 
parallel MD simulations. This approach allow to tune the bias only for a subset 
of the overall potential energy component of the system, instead of the total 
energy as happens in the case of T–REMD110. It follows that transitions are 
promoted thanks to a fewer number of MD replicas. In the work of Wang et 
al.111 H–REMD technique was able to enhance the sampling of putative binding 
modes of three known ligands to T4 lysozyme L99A. 
  
  
27 	   INTRODUCTION	   	  
	   	  
27 
1.2.3 METHODS THAT REQUIRE THE PRELIMINARY 
 DEFINITION OF COLLECTIVE VARIABLES 
 
In physics the degrees of freedom embody all the variables that describe 
the possible configurations of a system, allowing describe it from a mechanic 
point of view. In a chemical system, modelled by means of molecular mechanics, 
these degrees of freedom can be represented by the force field equation 
parameters. Moreover, by mathematically combine more degrees of freedom is 
possible to define order parameters, which are reduced descriptor for a subset of 
degrees of freedom. Some examples of order parameters are angles formed by 
non-bonded atoms or distances between groups of atoms, but more complex, 
experimentally-derived order parameters are normally employed112,113.  
Before to perform a MD simulation is possible to define one or more 
order parameters, usually named as collective variables (CVs), able to describe 
the system transition the user is interested in: during the simulation, if an energy 
bias is added to the system along these CVs, the probability of observe the 
transition results enhanced. Important MD techniques that employ the bias of a 
set of CVs are metadynamics, steered MD, umbrella sampling (US) and 
temperature accelerated MD (TAMD).  
After its first definition and application on simply chemical systems114 
(the dissociation of NaCl and the isomerization of the Alanine dipeptide in 
water), metadynamics soon demonstrated its potential usefulness in 
reconstructing the binding of chemical fragments on the enzyme β-Trypsine115. 
The algorithmic scheme behind metadynamics can be recapped as the seeding, at 
discrete time intervals, of a history–dependent energetic term centred along the 
predefined set of CVs (Figure 12). When the energetic bias is added at a certain 
instant, the probability that the system will revisit that specific configuration is 
decreased according to the shape of the energetic Gaussian function that is 
supplied. Thanks to this theoretical approach is possible to fill energy minimum 
on the energy surface defined by the CVs, therefore increasing the transition 
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probability from a basin to another one (e.g. the ligand bound and unbound 
states)116.  
 
 
Figure 12. Example of metadynamics simulation that bias one CV (denoted as s). The 
time t is measured by counting the number of Gaussians deposited. At the beginning of 
the simulation the system is in the minimum B, then, after 135 energy depositions, it 
experiences a transition to the minimum A, which, in turns, is filled after 810 bias 
cycles; the system is then allowed to explore minimum C. (Top) Time evolution of the 
collective variables during the simulation. (Bottom) Representation of the progressive 
filling of the potential energy minimums by means of the Gaussians deposited along the 
trajectory. (Adapted from ref 116). 
 
In general, the definition of the order parameters that well describe the 
binding or unbinding events is not trivial. Crucial aspects to consider are the 
height and the width of the Gaussian energetic term added: as a rule of thumb, 
the height of the function should be much smaller than the highest energy 
barrier characterizing the process, while the width should be small enough to 
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track FES containing many basins connected by narrow paths117. Regarding this 
latter point, Branduardi et al. proposed the adaptive Gaussians metadynamics 
approach, able to adjust the Gaussians variance on the fly, on the basis of the 
local properties of the energy surface118. Last but not least, as the error 
introduced during metadynamics is inversely proportional to the square root of 
the time deposition119, the energetic bias addition should not be too much 
frequent. 
More recently, issues related to the overfilling effect of metadynamics (an 
excessive energy seeding that may lead to the exploration of regions of the space 
that are too high in energy and therefore associated to protein unfolding) have 
inspired the development of the well-tempered metadynamics116,120 (WTmetaD): 
by tuning a new threshold parameter is possible to automatically limit the energy 
surface exploration to the physically interesting region, minimizing the bias 
added according to the energy already provided to the system. An elegant 
application of WTmetaD was the unbinding simulation of the selective COX-2 
inhibitor SC-558121. Interestingly, findings highlighted the possibility that SC-558 
engages COX-2 with two different binding poses, providing an explanation for 
the increased residence time in COX-2 for ligands structurally-related to SC-558 
(Figure 13).  
Binding of benzamidine on β-Trypsine and of SC-558 to COX-2 were 
also reconstructed implementing the so called funnel restraint potential in 
combination with WTmetaD: the core of this alternative MD methods is the 
introduction of a funnel-shaped restraint potential that limit the sampling of the 
ligand in the bulk solvent, speeding up the overall binding and unbinding 
simulation time122. 
Recently, Pratyush et al. provided a first attempt of to derivate kinetics 
rate values using WTmetaD by simulating the isomerization of the alanine 
dipeptide123,124. Salvalaglio et al. later introduced a posteriori statistical analysis 
(based on Poisson statistic) that establishes the reliability of the kinetics values 
thus generated124. In a very recent application of the former approach with a 
Markov State Model construction, the benzamidine unbinding mechanism from 
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β-Trypsin was completely disclosed125. Interestingly, beside the starting 
crystallographic binding pose, one alternative bound conformation and one 
metastable intermediate state were detected. Furthermore, the apo-form of the 
enzyme was suggested as existing in two different conformations: one 
characterized by the loop L in its crystallographic form (available for further 
binding), the other instead presenting a distorted loop L (protein is temporarily 
inactive). 
 
 
Figure 13. Dissociation energy surface of the COX-2 inhibitor SC-558. It was 
reconstructed as a function of the distance between the ligand and the protein and the 
value of a dihedral angle of the ligand. Four main energy basins A–D were found 
during the metadynamics (corresponding to the four displayed snapshots of the 
complex SC-558/COX-2): basin A, crystallographic pose; basin B, alternative pose; 
basin C, poses at gate site; basin D, external pose. (Adapted from ref 121). 
 
In general, binding and unbinding are influenced by multiple complex 
order parameters, such as the formation of intramolecular interactions, the 
rotations of entire protein domains or variations in the number of water 
molecules solvating the binding site. This complex scenario inspired Piana et al. 
to develop the so called bias–exchange metadynamics (BE-META)126: the heart 
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of this method is to exchange the CVs to bias between different parallel MD 
simulations, in order to sample a large number of different degrees of freedom 
of the system and, therefore, to explore energetic barriers orthogonal to the 
classic distance–based reaction coordinates. One of the first pharmaceutical 
application of BE-META was performed on the binding mechanism of the 
peptide substrate to HIV-1 protease127. 
Moving to further CVs–biasing methods, during a steered MD (SMD) 
simulation the transition between bound and unbound states is achieved by 
biasing the system energy with a harmonic potential, usually added on the 
protein–ligand distance. During the transition, is possible to compute the 
external work performed on the system, keeping track of energetic barriers along 
the unbinding pathway  128,129. While the first SMD application on unbinding 
simulations was performed on the dissociation of the complex biotin–
streptavidin39 by Grubmuller et al., more recent works employed this technique 
to study both binding 130and unbinding mechanisms. Among these latter fall the 
study of Favia et al., that sequentially applied SMD and metadynamics in order to 
reconstruct the dissociation mechanism of the endogenous hormone cortisone 
from the catalytic site of the enzyme 11β-HSD-1131: the authors first applied the 
SMD approach to sample different exit pathways, then tuned the selection of the 
CVs to bias on the basis of the trajectory that required the lower amount of 
work for the dissociation. SMD was also used to compare the unbinding force 
profiles of etoposide and some its analogs from the type II topoisomerase 
F14512132, as well as for discriminate active cyclin-dependent kinase 5 (CDK5) 
inhibitors from inactive ligands133.  
A SMD–related methodology is the random expulsion MD134 (REMD), 
during which the direction of the additional force is chosen randomly every time 
the ligand velocity falls below a predefined value (likely due to the encounter of 
relatively rigid parts of the protein). In a REMD application, a total of 360 short 
unbinding event of dihydroxyvitamin D3 from its receptor were reproduced135, 
highlighting different putative pathways. REMD and SMD together, indeed, 
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were employed to study binding and unbinding mechanisms of the inhibitor GS-
461203 on hepatitis C virus (HCV) non-structural protein 5B (NS5B)136.  
Umbrella sampling (US) represents the first CV–biasing method, 
developed137 with the aim of compute the free energy change implied in a 
thermodynamic transition. Chosen a CV to bias (for pharmaceutical applications 
usually is the distance between the ligand and the binding site) the ligand is 
moved in a discrete way along the CV by performing several parallel short MD 
simulations (called “windows”, Figure 14).  
 
 
Figure 14. Example of an umbrella sampling workflow. (A) During different windows 
the position of the restrained ligand is sampled along the CV (reaction coordinate); (B) 
the probability distribution for each window is computed  (using a 0.1-Å bin width in 
this case); (C) the energy surface along the CV (PMF) is calculated considering different 
resolutions of the grid elements. (Adapted from 138). 
 
During each window the ligand position x is subjected to an harmonic 
potential that allow to quantify the energy characterizing the regions along the 
pathway. The probability distribution of the ligand positions from each window 
is used to reconstruct the energy surface along the CV, by means of a post 
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processing analysis. From this point of view, the most common methods 
employed is the weighted histogram analysis method (WHAM)139, which 
integrates the probability distribution considering both the bin chosen for its 
construction and the bias applied during the simulation. It follows that the 
distance between consecutive ligand positioning from a window to the 
consecutive one, as well as the value of the force constant used, can heavily 
influence the final result of the this approach. As a rule of thumb, the force 
constant applied should be large enough to allow the system to overcome 
energetic barriers, but at the same time not too large, in order to avoid very 
narrow positional distributions140. Notably, US was applied to a number of 
biological systems in order to energetically and kinetically characterize the 
putative binding of both small molecules and peptides138,141.  
A peculiar CV–biasing technique is represented by the temperature 
accelerated molecular dynamics (TAMD)142. TAMD consists in sampling along a 
set of CVs by applying a harmonic force coupled to a fictitious particle thermally 
kept at higher temperature. The idea is to increase the Brownian motion only on 
few degrees of freedom, while the rest of the system remain distributed at the 
real temperature according to Boltzmann distribution. Dong et al. applied 
TAMD to the unbinding of the adenosine receptor inhibitor ZM24138521. The 
authors simulated 10 dissociation events and detected a set of key protein 
residues later investigated in accurate mutation studies, as well as multiple 
distinct consecutive steps along the pathways. Experimental outcomes 
highlighted the importance of the hydrogen bond network at the extracellular 
vestibula involving the ligand, His264 and Glu169, responsible of slowing down 
the dissociation rate, due to the energy required for breaking these favourable 
interactions.  
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1.3 G PROTEIN-COUPLED RECEPTORS AND ADENOSINE 
 RECEPTORS 
 
G protein–coupled receptors (GPCRs) represent the most numerous 
family of membrane proteins (encoded by more than 800 genes in the human 
genome143) and mediate cellular responses to a wide range of stimuli, which 
comprise hormones, neurotransmitters and photons144. According to the 
GRAFS 143 nomenclature system, GPCRs can be classified into five families145: 
 
•  rhodopsin-like: is the largest GPCRs family. Members’ diversity is mainly 
within the transmembrane (TMs) regions; 
• secretin-like: is a small family of GPCRs characterized by an extracellular 
hormone-binding domain. Members share between 21 and 67% of 
sequence identity; 
• adhesion: is the second largest GPCR family in humans. Members display 
a GPCR proteolytic (GPS) domain; 
• metabotropic glutammate: includes metabotropic glutamate receptors 
(GRMs), GABABRs, the calcium-sensing receptor (CASR) and taste 
receptors;  
• class F (Frizzled/Smoothened): consists of frizzled receptors, 
smoothened receptor (SMO) and teste2 receptors; 
 
GPCRs are topologically characterized by three elements (Figure 15): 1) 
the extracellular region, consisting in the N terminus and three extracellular 
loops (EL1–EL3) and responsive for ligands’ access modulation; 2) the 
transmembrane region (TM), which spams the membrane with seven α-helices 
(TM1–TM7) and shape the orthosteric binding site; 3) the intracellular C 
terminus, comprising three intracellular loops (IL1–IL3) and interfacing with the 
effector proteins. 
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Figure 15. Generic structure of GPCRs. N terminus and extracellular 
loops are different, depending on the family. TM helices are shown as green 
cartoon. Amino acids are numbered using the Ballesteros/Weinstein numbering 
system. (Adapted from ref 146).  
 
Notably, in the extracellular region a conserved disulphide bridge links 
TM3 and EL2, stabilizing the overall protein structure limiting the degree of 
conformational changes of this region during receptor activation147. Further 
significant structural convergence is the 'ionic lock' between the highly 
conserved E/DRY motif on TM3 and a glutamate residue on TM6 (Figure 16): 
these amino acids form a network of interactions that stabilize the inactive-state 
conformation148. At the end of TM7 there is another important structural 
element, which participates in conformational changes associated with GPCR 
activation: the conserved NPXXY motif149: as evinced from X-ray crystal 
structures, a proline causes a distortion in the helical structure, allowing a 
tyrosine side chain to lie into a pocket formed by TM2, TM3, TM6 and TM7. 
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Figure 16. Location of some important conserved residues, probably part of a common 
pathway for propagating conformational changes from the orthosteric pocket to the G-
protein coupling domains. Cluster of water molecules from (coloured spheres) are 
shown as spheres. Amino acids are numbered using the Ballesteros/Weinstein 
numbering system. (Adapted from ref 146). 
 
Variations in ELs, TMs helices, and side chains create a variety of 
orthosteric binding sites in the different GPCR subfamilies, reflecting the 
diversity of their corresponding ligands, as exemplified in Figure 17150. In general, 
binding sites are characterised by the presence of at least one key H-bonding or 
ionic interaction, as well as lipophilic hotspots, which are an important driving 
force of ligand interactions151. 
Experimental evidences outline that GPCRs exist in a dynamic 
equilibrium between inactive and active states (Figure 18) and the presence of 
the heterotrimeric G protein allow the receptors to reach the signaling state150. 
The energy difference between two states drives the transition probability 
between conformations (is a function of the energy barrier height between the 
two states). In absence of agonists, GPCRs have a basal activity152: energy 
changes occurring after ligand binding can modify the energy barrier between 
the two states or their stability (Figure 18). From this standpoint, inverse 
agonists shift the equilibrium toward inactive states, decreasing the level of basal 
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activity, whereas neutral antagonists do not affect the basal equilibrium. Binding 
of agonists shifts the equilibrium toward the activated states, which are 
characterized by large-scale conformational changes at the receptor's intracellular 
side153. 
 
 
Figure 17. Examples of different orthosteric binding pockets in GPCRs. Complexes are 
shown as molecular surfaces; GPCRs subtypes with similar pockets are highlighted. 
(Adapted from ref 150). 
 
 
Figure 18. Simplified GPCRs energy landscape. (a) Conformational states of an apo 
GPCR; the inactive state is more stable (therefore more populated). (b) Agonist (or 
partial agonist) binding reduce the energy barrier and/or the energy of the active 
conformation. (c) Binding of an inverse agonist increases the energy barrier and/or 
reduces the energy of the inactive state conformation. (Adapted from ref 147). 
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As shown in Figure 19, agonist–bound active conformation of the 
GPCRs can couples to heterotrimeric G proteins, which are formed by Gα, Gβ 
and Gγ subunits. Subsequently, GTP–bound Gα subunit separates from βγ and 
interacts with an effector, such as phospholipase C (PLC) or adenylyl cyclase 
(AC), initiating a second messenger cascade (usually cyclic AMP, inositol 
phosphates or Ca2+) that triggers different cellular responses. The 
phosphorylation of activated receptors, primarily by GPCR kinases, enables 
GPCRs to bind to multifunctional scaffold proteins, called β-arrestins and able 
to promote internalization of the receptor. The GPCR can then be recycled back 
to the cell surface without ligand, restarting the cycle154,155.  
From a molecular point of view, GPCRs activation driven by agonist 
binding mainly involves structural rearrangements in TM6. In the adenosine A2A 
subtype receptor (A2A AR)156 and the β2 adrenoreceptor (β2 AR)157 the 
interactions between Trp6.48 side chain and the agonist produce a shift of Trp6.48 
that stabilizes a swinging movement of helix VI (Figure 20, panel b) and allow 
the binding of the G protein (Figure 20, panel a). Moreover, at the cytoplasmic 
end of TM3, the Arg3.50 of the DRY motif directly interacts with a the C 
terminus of the G protein157.  
More recently the pharmacologic concept of biased agonism has become 
increasingly popular. After agonist binding, GPCRs manly operate by recruiting 
the G proteins, however, interaction with other proteins can influence signalling 
events158,159. Indeed, ligands can preferentially trigger some particular effects, 
influencing therapeutic signalling pathways or, on the contrary, triggering averse 
effects. A structural and mechanistic understanding of these phenomena is not 
yet well understood, as crystallographic methods are not able to probe the 
equilibrium between different conformations. From this standpoint, molecular 
modelling approaches can lead to new insights into GPCR function160 by means 
of molecular dynamics simulations, as for the observation of the β2 AR active-to-
inactive transitions161. 
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Figure 19. Activation cycle of GPCRs. Upon agonist binding, the receptor in the active 
conformation is able to bind the G protein, whose subunit Gα engage the effector 
protein triggering the second messenger cascade. β-arrestins are then responsible for 
GPCR internalization. (Adapted from ref 162). 
 
 
Figure 20. (a) Structure of β2 AR in complex with agonist BI-167107 and the G protein 
heterotrimer (PDB code 3SN6 157). (b) Conformational changes in helix VI upon β2AR 
activation. (Adapted from ref 150) 
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1.3.1 ADENOSINE RECEPTORS 
 
The importance of the adenosine receptors’ (ARs) pharmacology is daily 
experienced by million of coffee drinkers worldwide. Indeed, is well established 
that caffeine is able to non-selectively inhibit ARs subtypes163 (named A1, A2A, 
A2B and A3 respectively) leading to a range of different biological responses and 
suggesting the potential usefulness of ARs agonists or blocking agents164–166. 
Each of these four receptors plays an essential role in responding to 
adenosine in the central nervous system, regulating pain, cerebral blood flow, 
basal ganglia functions, respiration and sleep. From a structural point of view, 
the sequence similarity and identity between human ARs is relatively high and 
can be ascribed mainly to the transmembrane regions (TMs) and the orthosteric 
binding sites (Table 1), while extracellular loops characterized by an higher 
degree of variability. 
 
 
Table 1. ARs identity and similarity of sequence, comparison among subtypes. In 
general, orthosteric binding sites (lower chart) have a higher degree of conservation. 
  
41 	   INTRODUCTION	   	  
	   	  
41 
Extracellular sources of adenosine are mainly linked to the release 
through a membrane transporter, a cell damage or the nucleotidase–mediated 
hydrolysis of extracellular adenine nucleotide167 (Figure 21).  
Adenosine-mediated activation of the A1 AR inhibits adenylyl cyclase 
(AC) activity through Gi proteins168 and results in increased activity of 
phospholipase C (PLC)169. In cardiac muscle and neurons, A1 ARs activate 
pertussis toxin-sensitive K+ channels (responsible for bradycardic effect170), as 
well as KATP and Ca2+ channels.  
Adenosine binding to the A2A AR increases AC activity through a 
stimulatory Gs protein, which seems to be associated with A2AARs in the 
peripheral systems but not in the striatum, where A2AAR density is the highest 
but it mediate their effects mainly by activation of Golf, which also activate the 
AC171.  
A2B AR is coupled to both AC and PLC172,173, which is responsible of 
many of the important functions of A2B ARs174. Moreover, the arachidonic acid 
pathway was also demonstrated to be involved in A2B AR activation175. 
Finally, the A3AR pathway lead to the inhibition of AC176, stimulation of 
PLC177 and calcium mobilization. In cardiac cells, A3 AR induce protection 
through the activation of KATP channels178, while inhibition of proliferation was 
observed in human melanoma cells (via the ERK1/2 pathway)179.  
Among all the G-protein coupled receptors (GPCRs) superfamily 
members, A2A AR represents a fortunate starting point for structure-based drug 
design (SBDD) as, to date, despite the intrinsic difficulties in GPCRs 
crystallography180 20 X-ray structures have already been resolved: more precisely, 
A2A was disclosed in complex with both agonists156,181,182 (included a recent 
structure bound to an engineered G protein183) and antagonists184–189. 
Development of more selective compounds for adenosine receptor subtypes 
could provide a class of therapeutics for treating numerous human diseases, such 
as pain, Parkinson's disease, asthma, seizures, and many other neurological 
disorders (Figure 22).  
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Figure 21. Schematic representation of ARs activation pathways, adenosine extracellular 
formation and adenosine intracellular metabolism. (Adapted from ref 190). 
 
 
Fig. 22. Therapeutic potential applications of adenosine agonists and antagonists. A1 
AR is expressed in the brain, heart, adipose tissue, stomach, vas deferens, testis, spleen, 
kidney, aorta, liver, eye and bladder. A2AAR is highly expressed in the central nervous 
system and in the immune cells, heart, lung and blood vessels. A2BAR is located at low 
levels in almost all tissues. A3ARs have been detected in various tissues including testis, 
lung, kidney, placenta, heart, brain, spleen and liver. (Adapted from ref 166).  
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ARs, likewise many other GPCRs191,192, can be selectively targeted with 
allosteric modulators. At molecular level, an allosteric modulator amplifies the 
action of agonists by stabilizing the intermolecular complex formed by 
adenosine and AR increasing the tissue specificity of the drug, that would act in 
concert with locally increased adenosine under pathological conditions, having 
little effect on sites where there are low basal adenosine levels. Recently an 
allosteric regulatory site for sodium was identified 189,193 and constant efforts are 
focused on the development of methods able to detect allosteric sites in 
ARs100,194–196. 
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Computational chemists are constantly looking for new methods able to 
furnish a rationale for experimental data or to supply new hypothesis for 
applicative fields. From this standpoint, we have recently developed the 
supervised molecular dynamics (SuMD), a computational too able to gain 
insights at molecular level about ligands binding to macromolecules. Aims of this 
Ph.D project were to extensively validate the SuMD method on a wide range of 
endogenous targets, as well as to reconstruct the binding mechanisms of several 
adenosine receptor ligands. Better knowledge of the dynamic intermolecular 
recognition processes can allow propose structural modification in order to 
improve the kinetic behaviour of ligands as well as to decipher possible role of 
protein mutations in intermolecular recognitions. 
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The overall Ph.D. project was divided in different stages. A preliminary 
phase was focused on the application of the supervised molecular dynamics 
(SuMD) methodology: we tested this computational approach on a wide number 
of both cytosolic and membrane proteins with the aim of validate its ability to 
reconstruct X-ray determined intermolecular complexes as well as to elucidate 
the pathways the ligands putatively follow. This first part of the work resulted in 
the publication: 
 
• “Deciphering the Complexity of Ligand-protein Recognition Pathways 
using Supervised Molecular Dynamics (SuMD) Simulations”. 
 
Following SuMD applications concerned the binding mechanisms of the 
endogenous effector adenosine (to the receptors subtype A2A) and the A3 
positive allosteric modulator (PAM) LUF6000. Scientific publications related to 
these exertions are the following: 
 
• “Exploring the recognition pathway at the human A2A adenosine receptor 
of the endogenous agonist adenosine using supervised molecular 
dynamics simulations”; 
 
• “Understanding allosteric interactions in G protein-coupled receptors 
using Supervised Molecular Dynamics: a prototype study analysing the 
human A3 adenosine receptor positive allosteric modulator LUF6000”. 
 
In the last section of the chapter we introduce an overview on how to 
link different computational techniques, creating a complete pipeline able to 
facilitate the “hit to lead” compound optimization process. The related 
publication is: 
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• “New Trends in Inspecting GPCR-ligand Recognition Process: the 
Contribution of the Molecular Modeling Section (MMS) at the University 
of Padova”. 
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3.1 Deciphering the Complexity of Ligand-protein 
Recognition Pathways using Supervised Molecular 
Dynamics (SuMD) Simulations. 
 
Alberto Cuzzolin, Mattia Sturlese, Giuseppe Deganutti, Veronica Salmaso, 
Davide Sabbadin, Antonella Ciancetta and Stefano Moro* 
 
Abstract 
Molecular recognition is a crucial issue in interpreting the mechanism of known 
active substances as well as in the development of novel active candidates, since 
both thermodynamic and kinetic aspects greatly affect the understanding of 
ligand-mediated signal transmission in living organisms or whether a chemical 
compound can be transformed in a drug candidate. The physicochemical bases 
governing the optimization of thermodynamic aspects of ligand binding are 
relatively well understood, but they remain still poorly comprehend for binding 
kinetics. Unfortunately, simulating this binding process is still a challenging task 
because it requires classical MD experiments in a long microsecond time scale 
that is affordable only with a high-level computational capacity. In order to 
overcome this limiting factor, we have recently implemented an alternative MD 
approach, named supervised molecular dynamics (SuMD) specifically in the field 
of G protein-coupled receptors (GPCRs). SuMD enables the investigation of 
ligand-receptor binding events independently from the starting position, 
chemical structure of the ligand, and also from its receptor binding affinity.  
In this Article, we would like to present an extension of SuMD 
application domain including different types of proteins compared to GPCRs. In 
particular, we decided to deeply analyze the ligand-protein recognition pathways 
of six different case studies that we grouped into two different classes: globular 
and membrane proteins. Moreover, we would like to introduce the SuMD-
Analyzer tool that we have specifically implemented to help the user in the 
analysis of the SuMD trajectories. Finally, we will emphasize the limit of SuMD 
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applicability domain as well as its strengths in analyzing the complexity of ligand-
protein recognition pathways.  
 
Introduction  
The essential features of ligand-protein interaction are very often 
summarized under the expression "molecular recognition" incorporating both 
thermodynamic aspects (quantified by the Kd, the equilibrium dissociation 
constant) and kinetic aspects of ligand binding (reflected by the rate constants 
kon and koff). Consequently, molecular recognition is thus a crucial issue in 
interpreting the mechanism of known active substances as well as in the 
development of novel active candidates, since both thermodynamic and kinetic 
aspects greatly affect the understanding of ligand-mediated signal transmission in 
living organisms or whether a chemical compound can be transformed in a drug 
candidate1.  
The physico-chemical bases governing the optimization of 
thermodynamic aspects of ligand binding are relatively well understood but, 
unluckily, they remain still poorly comprehend for binding kinetics. In fact, the 
equilibrium dissociation constant value depends on the free energy difference 
between the ligand-protein bound and unbound states, both of which are 
chemically stable and generally experimentally observable. On the contrary, kon 
and koff rate constants depend on the height of the free energy barrier separating 
those states and, in particular, the highest free energy barrier defined as 
transition state characterized only by a fleeting existence2. Consequently, the 
major challenge in the optimization of the kinetics parameters is the complexity 
in characterizing all plausible approaching pathways of the ligand to its protein. 
In fact, different approaching pathways can be characterized by different 
metastable intermediate states (referred also as meta-binding sites)3 connected to 
each other, and to the final bound state, by different transition states. 
Understanding the molecular interactions between ligand and protein 
during the approaching pathways is thus central to the deep understanding and 
to the rational control of ligand binding kinetics. Even though experimental 
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techniques for measuring the kinetic parameters of ligand binding have existed 
for decades, all of them only provide indirect evidence about transient structures 
visited along a ligand-binding pathway2. Alternatively, computational methods, 
and in particular molecular dynamics (MD) simulations, can provide detailed 
structural information on metastable intermediate states (meta-binding sites) and 
transition states at the atomistic level of detail4. Due to increases in 
computational power, it has recently become possible to simulate the full 
process of spontaneous ligand-protein association which typically occurs on the 
microsecond timescale, providing direct access to detailed information on 
binding mechanisms that have been difficult to access experimentally4,5. 
Unfortunately, simulating this binding process is still a challenging task because 
it requires classical MD experiments in a long microsecond time scale that is 
affordable only with a high-level computational capacity. However, the 
probability of reproduce ligand- protein binding or unbinding event on an 
accessible timescale can be enhanced through the introduction of biased 
potentials that facilitate the crossing of energy barriers or the application of 
external forces on the ligand, respectively6. An alternative strategy that does not 
require the introduction of biases or external forces and enables to explore the 
ligand-protein approaching path in nanosecond simulation time scale has been 
recently proposed by us specifically in the field of G protein-coupled receptors 
(GPCRs)7,8 The “supervised molecular dynamics” (SuMD) approach exploit a 
tabu-like algorithm to monitor the distance between the center of masses of the 
ligand atoms and the protein binding site in short (600 ps) standard MD 
simulations (Figure 1, left panel). According to this strategy, an arbitrary number 
of distance points is collected “on the flight” at regular intervals and fitted into a 
linear function f(x)=mx. If the slope (m) is negative, the ligand-receptor distance 
is likely to be shortened and the simulation is restarted from the last set of 
coordinates. Otherwise, the simulation is restored from the original set of 
coordinates and started over. The supervision is repeated until the ligand-
receptor distance is less than 5 Å. The results of a SuMD simulation are 
displayed in a graph reporting the interaction energy toward the distance 
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between the ligand and the binding site (Figure 1, right panel). We have recently 
applied the SuMD approach to interpret at the molecular level: i) the binding of 
different antagonists at the human A2A adenosine receptor (hA2A AR) by 
detecting and characterizing a possible energetically stable meta-binding site7 , ii) 
the binding of the natural agonist adenosine at the hA2A AR by detecting and 
characterizing a possible energetically stable meta-binding site9, iii) the positive 
allosteric modulation mediated by LUF6000 toward the human A3 adenosine 
receptor (hA3 AR) by suggesting at least two possible mechanisms to explain the 
available experimental data10, and iv) the binding of different ligands at the 
human P2Y12 receptor by detecting and characterizing again possible 
energetically stable meta-binding site11.  
 
 
Figure 1. a) Schematic representation of Supervised Molecular Dynamics (SuMD) 
algorithm (left) and the outcoming ligand−protein interaction energy landscape. 
Interaction Energy values: kcal mol-1.  
 
In the present work, we would like to present an extension of SuMD 
application domain including different types of proteins compared to GPCRs. In 
particular, we decided to deeply analyzed the ligand-protein recognition 
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pathways of six different case studies that we grouped into two different classes 
of proteins: globular and membrane proteins, as summarized in Table 1. 
Moreover, we would like to introduce the SuMD-Analyzer tool that we have 
specifically implemented to help, also a non-expert user, in the analysis of the 
SuMD trajectories.  
 
Table 1 - Structural summary of the selected ligand-protein PDB ID are reported 
Globular System 
PDB Protein Ligand 
Resolutio
n [Å] 
Affinity 
Ligand 
MW 
Ref. 
2ZJ
W 
CK2 Ellagic Acid 2.40 Ki=0.04 µM 302.197 41 
13GS 
GSTP1-
1 
SASP 1.90 Ki=24 µM 398.39 44 
4K7I PRDX5 
Benzen-1,2-
diol 
2.25 Ki=1500µM 110.11 45 
2VD
B 
HSA (S)-naproxen 2.25 
Ki=1.2-
1.8µM1 
230.25 49,58 
Transmembrane Systems 
PDB 
Protei
n 
Ligand 
Resolutio
n [Å] 
Affinity 
Ligand 
MW 
Ref. 
3GW
W 
LeuT 
(S)-
dluoxetine 
2.46 
IC50=355m
M 
345.79 51 
2YDV 
hA2AA
R 
NECA 2.60 Ki=13.8nM 308.29 55 
 
Materials and Methods  
 
General .    
All computations were performed on a hybrid CPU/GPU cluster. MD 
simulations were carried out with the ACEMD engine12 on a GPU cluster 
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equipped with four NVIDIA GTX 580, two NVIDIA GTX 680, three NVIDIA 
GTX 780, and four NVIDIA GTX 980. Before running SuMD simulations, the 
following preliminary phases were carried out: i) protein-ligand system 
preparation; ii) ligand parameterization; iii) solvated system setup and 
equilibration. Two different protocols based on AMBER1213/General Amber 
Force Filed (GAFF)14 and the CHARM2715/CHARMM General Force Field 
(CGenFF), force fields combinations were adopted for globular and 
transmembrane systems, respectively16,17.  
 
Systems Preparat ion.   
Protein-ligand complexes were retrieved from the RCSB PDB database18. 
Proteins structures were prepared with the protein preparation tool as 
implemented in MOE19: hydrogen atoms were added to the complex and 
appropriate ionization states were assigned by means of the Protonate-3D tool20. 
Missing atoms in protein side chains were built according to either the 
AMBER1213 or the CHARM2715 force field topology. Missing loops were 
modeled by the default homology modelling protocol implemented in the MOE 
protein preparation tool. Non- natural N-terminal and C-terminal were capped 
to mimic the previous residue. For each considered system, the conformer with 
highest occupancy was selected whenever available. To avoid protein-ligand long 
range interactions in the starting geometry, the ligand was then moved at least 15 
Å from any protein atom.  
 
Ligand Parameter izat ion.   
Globular sys tems.   
For the MD simulations based on the AMBER12 force field13, the ligands 
were subjected to two energy minimization steps with MOPAC201221 using 
PM6 method22 and Gaussian 0923 (basis set: HF/6-31G*). After geometry 
minimization, ligand parameters were derived with GAFF14 as implemented in 
ambertools201413  by using antechamber and parmchk tools. RESP partial 
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charges where calculated with Gaussian 0923 following the procedure suggested 
by antechamber. 
  
Transmembrane sys tems.   
For the MD simulation based on the CHARMM27 force field24, initial 
parameters for the ligands were retrieved from the paramchem service and 
subsequently optimized consistently to CGenFF16,25 at the MP2/6-31G* level of 
theory26 by using Gaussian 0923 and the Force Field Toolkit27 implemented in 
the VMD engine28.  
 
Solvated System Setup and Equi l ibrat ion  
Globular Systems.   
Protein-ligand complexes were assembled with tleap tool using 
AMBER14SB29 as force field for the protein29. The systems were explicitly 
solvated by a cubic water box with cell borders placed at least 12 Å away from 
any protein or ligand atom using TIP3P as water model30. To neutralize the total 
charge Na+/Cl- counter-ions were added to a final salt concentration of 0.150 M. 
The systems were energy minimized by 2000 step with conjugate-gradient 
method, then 50000 step of NVE (100 ps) followed by 1 ns of NPT simulation 
were carried out, both using 2 fs as time step and applying an harmonic 
positional constrain on protein and ligand atoms gradually reduced with a scaling 
factor of 0.1. Pressure was maintained at 1 atm using a Berendsen barostat31.  
The Langevin thermostat was set with a low damping constant of 1 ps-1 32. Bond 
lengths involving hydrogen atoms were constrained using the M-SHAKE 
algorithm33. The MD productive runs were conducted in a NVT ensemble. 
Long-range Coulomb interactions were handled using the particle mesh Ewald 
summation method (PME) setting the mesh spacing to 1.0 Å34. A non-bonded 
cut-off distance of 9 Å with a switching distance of 7.5 Å was used.  
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Transmembrane Systems.   
Transmembrane proteins were embedded in a 1-palmitoyl-2- oleoyl-
snglycero-3-phosphocholine (POPC) lipid bilayer according to the suggested 
orientation reported in the Orientations of Proteins in Membranes (OPM) 
database35. The systems were solvated with TIP3P30 water using the program 
Solvate 1.036 and neutralized by Na+/Cl- counterions to a final concentration of 
0.154 M.  The systems were then equilibrated through a two steps procedure: in 
the first stage, after 2000 cycles of conjugate-gradient minimization algorithm (in 
order to reduce steric clashes produced by the system manual setting), 10 ns of 
MD simulation were performed in the NPT ensemble, restraining ligand and 
protein atoms by a force constant of 1 Kcal mol-1 Å-2. The temperature was 
maintained at 298 K using a Langevin thermostat with a low damping constant 
of 1 ps-1 32 pressure was maintained at 1 atm using a Berendsen barostat31, bond 
lengths involving hydrogen atoms were constrained using the M-SHAKE 
algorithm33 with an integration timestep of 2 fs. In the second stage, once water 
molecules diffused inside the protein cavity and the lipid bilayer reached 
equilibrium, the force constant was gradually reduced to 0.1 Kcal mol-1 Å-2 for 
the next 10 ns of MD simulation.  
 
Supervised Molecular Dynamics  (SuMD)  
SuMD is a command line tool written in python, tcl, and bash that 
operates the supervision of MD trajectories according to the algorithm that has 
been previously described7. The program exploits Visual Molecular Dynamics 
(VMD) and Gnuplot functionalities28,37. In its current implementation, SuMD is 
interfaced with the ACEMD12 engine and supports AMBER and CHARMM 
force fields.  
 
SuMD Input f i l e s .   
SuMD requires a configuration file (selection.dat, Figure S1) organized in 
three major sections containing information about: i) the system; ii) the 
supervision procedure; and iii) the simulation settings. In the system settings 
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section, the following details about the molecular system need to be provided: i) 
the pdb file name containing the starting coordinates; ii) the 3-letter code name 
of the ligand; and iii) the residues describing the target binding site. In the 
supervision settings section, the following values are declared: i) the slope 
threshold (default value: 0); and ii) the number of maximum consecutive failed 
steps (default value: 33) to stop the simulation. In the simulation settings section, 
the following details must be specified: i) the force field to use; ii) the parameter 
file; iii) the GPU device ID to which the calculation will be addressed. In this 
section, a Boolean operator manages the introduction of a randomization step 
that varies the position of the ligand through a 600 ps of non-supervised MD 
simulation. In the same directory where SuMD is launched, a file containing the 
cell dimension as well as a parameter file (prmtop/psf with the same name of the 
pdb) must also be provided.  
 
SuMD Main Code.   
The workflow of the SuMD main code is reported in Figure 2A. As 
depicted, at the beginning of the simulation SuMD detects the atoms that 
identify the ligand and the target binding site, to define the distance between 
their mass centers dcm(L-R)  that will be monitored. Then, a series of 600 ps 
classical MD simulations are performed. After each simulation, five dcm(L-R) 
distance points are collected at regular intervals of 75ps. Using these points, the 
slope value (m) is derived by a linear fitting. As previously described, if the 
resulting slope m is negative or below the user selected threshold (i.e. the distance 
dcm(L-R) is decreasing), the next simulation step starts from the last set of 
coordinates produced, otherwise the simulation is restarted by randomly 
assigning the atomic velocities. To avoid problematic starting geometries (i.e. 
geometries prone to lead to dead-end pathway), in the first simulation step,  
SuMD supervises the distance dcm(L-R) with a maximum threshold  of 31 failed 
attempts (Preliminary Run). In the case this threshold is reached, SuMD 
callbacks a randomization process on the set of coordinates supplied by the user 
by a classical 600 ps MD simulation.   
 85 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
During the following steps, the simulations are perpetuated under the 
supervision rules. In particular, the first time a slope value below the threshold is 
recorded, the program enters the so- called “SuMD Run”. When the distance 
dcm(L-R) drops below 5 Å the supervision is disabled and the simulation proceeds 
though a classical MD simulation. At the end of the simulation, only the 
productive steps are saved, chronologically numbered and stored in a separate 
directory.  
 
SuMD log f i l e .   
At each SuMD simulation step, a log file (Figure 1S) is updated collecting 
information about: i) the step number; ii) the dcm(L-R) distance; iii) the slope 
value (m); iv) the electrostatic and van der Waals potential energy contributions 
of the ligand-receptor interaction energy (IE). A counter keeps trace on how 
many times each SuMD step has been attempted. Furthermore, three counters 
corresponding to the dcm(L-R) distance ranges 0-2 Å, 2-5 Å, and 5-9 Å are 
reported. These distances monitors how many times the binding site is 
approached, i.e. how often the dcm(L-R) distance lies below the long-range 
interaction cutoff. These counters determine the program termination criteria 
(see following section) and, according to the binding site definition supplied by 
the user, they might represent: the target binding site, its neighbors, and putative 
allosteric/meta-binding sites, respectively.  
 
SuMD Terminat ion Cri ter ia .   
A SuMD simulation is terminated when one of the following criteria is 
satisfied: i) no negative slope (m) values are recorded for a user-selected number 
of steps (33 consecutive steps by default); ii) one of the distance counters 
reaches a maximum value of 19 (i.e. the dcm(L-R) lies in the same region for 11.5 
nonconsecutive nanoseconds). 
 
 86 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
Figure 2. (A) Workflow of the SuMD main code (B) Workflow of the SuMD-Analyzer 
tool. 
 
SuMD-Analyzer Tool  
 The SuMD-Analyzer is a standalone tool written in python, tcl, and bash 
to analyze the SuMD trajectories (Figure 2B). The tool is integrated with VMD28 
and UCSF Chimera38 for the graphical visualization and exploits Wordom39 and 
Gnuplot37 functionalities. The provided analyses cross over four different 
aspects: i) the ligand position, ii) the IE, iii) the per residue interactions, and iv) 
the replicas comparison.  
When the SuMD-Analyzer is launched, the trajectories produced by 
SuMD are merged and aligned to the starting reference structure using the 
RMSD tool in VMD by using alpha-carbon atoms for the superposition. The 
merged trajectory is subjected to a striding procedure picking one frame every 5 
through the VMD animate module.  
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Ligand Posi t ion.   
Two analyses follow the coordinates explored by the ligand during the 
SuMD trajectory (Figure 2B, green boxes): i) the Root Mean Square Deviation 
(RMSD); and ii) the so-called “Pollicino Analysis”. If a reference complex 
structure is available, the RMSD between the ligand and the reference 
coordinates supplied is computed along the trajectory. The calculation is 
performed on the heavy atoms of the ligand using the measure rmsd function 
implemented in VMD and the data obtained are plotted against the time using 
Gnuplot37 (Figure 2B, left green box).  
The Pollicino Analysis is a representation that graphically renders the 
recognition pathway explored by the ligand. At the end of each SuMD step, the 
coordinates of the ligand mass center are collected and clustered according to 
their dcm(L-R) using a threshold value of 2 Å. The coordinates belonging to the 
same cluster are averaged and represented by a sphere which radius depends on 
the population of the cluster. Arrows indicate the chronological order onto 
which the regions where the sphere reside are approached by the ligand mass 
center (Figure 2B, right green 22 box).  
 
Interac t ion Energy .   
The ligand-protein interaction is analyzed by means of the mdenergy 
function embedded into VMD. The electrostatic and van der Waals 
contributions to the potential energy are calculated for each frame and summed 
to obtain the total IE. With this value, two graphs are derived (Figure 2B, blue 
boxes): i) the “Interaction Energy Landscape”, and ii) the “Cumulative 
Interaction Energy”. The former chart displays the total IE profile with respect 
to the dcm(L-R)  through a colorimetric scale representing the IE value. Each 
point displayed in the chart represents the last position of the corresponding 
SuMD step (Figure 2B, left blue box). The  latter plot shows the cumulative sum 
of the total IE values for each frame against the time. Therefore, each point is 
the sum of all previous IE values. Changes in the observed trend highlight how 
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the variation of ligand conformation/position affects the IE (Figure 2B, right 
blue box).  
 
Per Res idue Interac t ions .  
A further set of analyses was developed to highlight the most important 
residues involved in the ligand recognition pathway (Figure 2B, upper magenta 
boxes): i) the “Protein-ligand Contacts Count”, and the ii) “Ligand-Protein 
Recognition Map”. In the first graph (Figure 2B, upper left magenta box), the 
residues more frequently approached by the ligand during the trajectory are 
reported and for each residue the total number of established contacts is 
rendered as histograms. In this representation, at each SuMD frame only the 
residues lying within a distance of 4 Å from any ligand atoms are considered. In 
the second graph (Figure 2B, upper right magenta box), the residue approached 
by the ligand are depicted with respect to the simulation time. In particular, each 
dot in the map represents a trajectory frame colored according to the total 
number of contacts the ligand has established with a particular residue. White 
dots means that, at the considered frame, the residue atoms are farther then 4 Å 
from ligand atoms, while green dots correspond to a contact event and the sum 
of the contact is coded by the light-green to dark-green scale.  
To support the user in the topological localization of the residues mainly 
interacting with the ligand during the trajectory, molecular 3D representations of 
the protein are automatically set using USF Chimera38 (Figure 2B, lower magenta 
boxes). In particular, the number of ligand- protein contacts is normalized and 
stored into the B-factor field of the involved residue in the protein pdb file. In 
the protein 3D representation “Chimera_count” (Figure 2B, lower left magenta 
box) the ribbons are colored according the so-derived B-factor values. A similar 
representation, “Chimera_time” (Figure 2B, lower right magenta box), is 
available with the color code (blue-to-violet) reflecting the chronological order 
onto which the residues have been approached by the ligand for the first time.  
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Repl i cas Analys i s .   
The “Replicas Analysis” (Figure 2B, violet box) is a manager that 
compares the molecular recognition event occurred in different SuMD replicas. 
The manager extracts from each trajectory the data regarding the ligand position 
and the IE, merges the data for each analysis in graphs colored according the 
replica number to better appreciate the differences.  
 
Results and Discussion  
 
Case Studies  Sele c t ion  
As already anticipated, in this work SuMD applicability domain has been 
extended using six different case studies, grouped into two major protein classes: 
i) globular systems, and ii) transmembrane systems (as summarized in Table 1). 
Specifically, considering the globular proteins we selected: a) the human Caseine 
Kinase 2 (CK2) in complex with Ellagic acid; b) the P1-1 isoform of Glutathione 
S-transferase (GSTP1-1) in complex with Sulphasalazine (2-hydroxy-(5-{[4-(2-
pyridinylamino)sulfonyl]phenyl}azo) benzoic acid, SASP); c) the human 
Peroxiredoxin 5 (PRDX5) in complex with a benzen-1,2-diol; and d) the human 
Serum Albumin (HSA) in complex with (S)-naproxen. Considering the 
membrane proteins, we selected: a) the Leucine transporter (LeuT) from Aquifex 
aeolicus in complex with (S)-fluoxetine; and b) the human Adenosine A Receptor 
(hA2A AR) in complex with the synthetic agonist 5'-N-
Ethylcarboxamidoadenosine (NECA). An overview of the structural features of 
the considered ligand-protein complex is reported in Figure 3 and briefly 
described in the following.  
CK2 is a ubiquitous and constitutively active serine/threonine kinase 
(PK) that phosphorylates more than 300 substrates. It is involved in the 
regulation of numerous cellular process such as cycle progression, apoptosis, 
transcription and viral infection40. The catalytic alpha subunit is composed by 
two lobes connected by a small loop called “hinge region”. The N- terminal lobe 
presents five β-strands and the α-helix C involved in the substrate recognition, 
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whereas the C-terminal lobe is composed of α-helices. All PKs present a glycine 
rich loop (P-loop), an activation loop, and a catalytic loop40. The X-ray complex 
highlights that the inhibitor binds to Lys49, Ser51and His160 as shown in Figure 
3A41. 
 
 
Figure 3. Overview of the X-ray protein-ligand complexes used as validation cases. On 
the top: Acid Ellagic-CK2, SASP-GSTP1-1, Benzen-1,2-diol-PDRX5; On the bottom: 
(S)-naproxen-HAS, (S)-fluoxetin-LeuT, NECA-hA2AAR. 
 
Glutathione S-transferases (GSTs) are homodimeric phase II 
detoxification enzymes, active in the bioconjugation of glutathione (GSH) to a 
wide range of both endogenous and exogenous molecules. The catalytic region 
of GSTs is topologically subdivided in two different site: i) the G-site, selective 
for GSH recognition and highly conserved crosswise GSTs isoforms, and ii) the 
H-site, less conserved and responsible for the binding of electrophilic 
molecules42. Isoform P1-1 probably represents the most studied GST and has 
been related to the development of tumors resistance towards numerous anti-
cancer drugs43. SASP, which is able to inhibit GSTs without acting as a co-
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substrate for the conjugation reaction with GSH, has been co-crystallized with 
GSTP1-1 and represents a starting point for structure-based design of new 
anticancer drugs44. The X-ray complex (Figure 3B) highlights that the inhibitor 
binds to a hydrophobic pocket formed by Phe8, Val10, Val35, Ile104 and 
Tyr108 side-chains. SASP phenyl ring and salicylic acid moiety are engaged in 
π−π stacking interactions with the aromatic side-chain of Phe8 and Tyr108, 
respectively, while the ligand carboxylate is involved in an electrostatic 
interaction with the Arg13 side chain.  
To extend the SuMD capabilities on low affinity ligand we selected the 
recently solved structure of PRDX5 in complex with a benzen-1,2-diol45. 
PRDX5 belongs to the ubiquitary peroxiredoxin family which role relies on the 
hydrogen peroxide and alkyl hydroperoxides reduction. PRDX5 plays a 
remarkable role in post-ischemic inflammations in the brain46,47. The catechol 
was identified by a fragment based screening and the dissociation constant was 
estimated in the millimolar range (Kd=1.5 +/- 0.5mM). More interestingly, the 
system was extensively characterized by NMR spectroscopy both with structure-
based experiments and ligand-based experiments, resulting in a solid model 
system for a low-affinity binding event45. In the X-ray complex (Figure 3C) the 
catechol ring is localized to the N-terminus of the second helix establishing a 
hydrogen-bond network with the backbone nitrogen of Gly46 and Cys47 
residues. The sidechain of Arg127 is oriented towards the hydroxyl moiety and 
contributes to the binding with an additional hydrogen bond. Similarly, the thiol 
group of Cys47 is faced to the catechol. The Pro40, Leu116 and Phe120 
establish hydrophobic interactions with the aromatic ring.  
The Human Serum Albumin (HSA) is a deeply investigated protein for its 
ability in bind a wide range of different molecules in human plasma. (S)-
naproxen strongly binds HSA and more interestingly in different sites depending 
on the presence of other small molecules (e.g. hormones, xenobiotic, fatty 
acids)48,49. The only structure available for this complex was obtained in presence 
of decanoic acid driving the accommodation of the naproxen molecule in  the IB 
site, a vast and hydrophobic pocket where a multitude of different ligand can be 
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hosted49.  In the IB site (S)-naproxen inserts its naphthalene scaffold within the 
hydrophobic pocket and interacts directly with the aliphatic tail of decanoic acid 
and the residues Ile142, Phe157 and Tyr161 (Figure 3D). The carboxylic group is 
partially exposed to the solvent but is surrounded by several charged residue 
forming the entrance of the pocket: Arg145, Lys 190 and in particular Arg186.  
Neurotransmitter sodium symporter (NSS) family includes the human 
serotonin transporter (SERT), norepinephrine transporter (NET) and dopamine 
transporter (DAT)50. To date, there is a lack of focused information about the 
structure of these important therapeutic targets. In recent past, the 
crystallographic structure of the LeuT from Aquifex aeolicus (a NSS family 
member) has been disclosed with the aim of better understand the basis for 
selective  serotonin re-uptake inhibitors (SSRIs) activity towards serotonin 
transporters51. LeuT-(S)-fluoxetine X-ray complex (Figure 3E) highlights 
hydrophobic contacts between the inhibitor and Leu29, Arg30, Tyr108 and 
Phe253 side chains. (S)-fluoxetine secondary amino group points towards the 
extracellular space and engage Asp401 in an electrostatic interaction, while the 
extracellular gate is locked by the salt bridge between Asp404 and Arg30.  
Moving to the last key study, adenosine receptors (ARs) belong to the G 
protein-coupled receptors (GPCRs) superfamily. The known four subtypes, 
termed adenosine A1, A2A, A2B and A3 receptors, are widely distributed in human 
body, involved in several physio-pathological processes and represent potential 
targets for the treatment of several diseases52. In the last decade, X-ray structures 
of the hA2A AR in complex with agonists and antagonists have been released 
thus offering the basis for molecular modeling investigation53 including also 
SuMD simulations7,54,10. Here we focus on the complex with NECA55 (Figure 
3F) that features a strong  polar interaction between the exocyclic amine group 
of NECA and the side chain of the conserved Asn253 residue; a hydrogen bond 
with the nitrogen atom of NECA acetamide moiety and the Thr88 side chain; 
and an aromatic π-π stacking with the conserved Phe168, located in the second 
extracellular loop (EL2), and hydrophobic contacts with, among others, the 
Leu249 side chain.  
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Globular Systems  
Acid Ellagi c -CK2 recogni t ion pathway.   
In the starting geometry the ligand was placed at a distance of 50 Å from 
the binding site. After the initial randomization step, the distance reduced to 43 
Å. As depicted in Figure 4A and shown in Video S1, the first interaction 
between the ligand and the protein is established after 2 ns of productive 
trajectory and is mediated Lys49 that directs the ligand to the P-loop of the 
kinase. As shown by the Pollicino analysis (Figure 4B), the ellagic acid 
approaches the region of the P-loop and mostly interacts with the Arg47, Lys49, 
Glu53 and the Lys71 (Figure 4A). These residues describe an interaction site, at 
10.5 Å where the ligand resides for about 6 ns. In facts, the ligand RMSD plot 
(Figure 4C) records stable values in the 2-8 ns time lapse. The IE with the 
protein in this site is about -20 kcal/mol (Figure 4D at dcm(L-R)= 10 Å); the Per 
Residue Contacts Count graph (Figure 4E) highlights that the above mentioned 
residues are those establishing the greatest number of contact, whereas the 
corresponding 3D models helps in identifying their location (Figure 4F) and  the 
chronological order at which they have been approached by the ligand (Figure 
5A). Approximately after 7 ns of simulation the ligand moves toward the 
orthosteric site, where Leu45 stabilizes its conformation and the side-chain of 
His160 hampers its passage. Through an interaction mediated by Arg43 the 
ligand overcomes the His160 gate and reaches new interaction site described by 
Asp120, Arg47, and Met163. The permanency in this site is about of 2 ns with 
an interaction energy of -51 kcal/mol (Figure 4C-D). Consistently, the RMSD 
plot presents another plateau in the time range 8-10 ns (Figure 4C) that 
corresponds to the swarm of dots in the IE Landscape at dcm(L-R) = 11 Å 
(Figure 4D). A further stabilizing interaction with the Asn118 induces a shift in 
the ligand position that places the ring system parallel to the β7-β8 strands 
(Video S1). 
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Figure 4. Acid Ellagic-CK2 recognition pathway. (A) Ligand-Protein Recognition Map 
(B) Pollicino Analysis (C) Ligand RMSD (D) IE Landscape (E) Ligand-Protein 
Contacts Count (F) Chimera contacts. 
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Figure 5. Acid Ellagic-CK2 recognition pathway. (A) Chimera time (B) Cumulative IE 
(C) Cumulative IE electrostatic contribution (D) Cumulative IE van der Waals 
contribution (E) Superimposition between SuMD endpoint conformation and X-ray 
binding mode. 
 
As shown in the Cumulative Ligand-Protein IE (Figure. 5B) and its 
corresponding decomposition into electrostatic and van de Waal contribution, 
(Figure 5C and D, respectively) the change in the slope indicates that new 
conformation has a lower interaction energy than the previous one.  
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In particular, as highlighted by the comparison of the graphs relative to the 
electrostatic and van der Waals contribution (Figure 5C and D, respectively), the 
stabilization can be ascribed by the establishment on an electrostatic interaction 
with Asp175. As result of the new interaction the ligand moves into the 
orthosteric site (Figure 5E) and interacts with Lys159, Val66, Val117, Val53, 
His115 and Lys68 by maintaining the same position is maintained till the end of 
the SuMD simulation. The RMSD plot shows another plateau from 10 ns to the 
end, whereas the IE Landscape indicates that in this time lapse the ligand is at a 
distance around 2.5 Å with an IE between -40 to -70 kcal/mol. 
The simulation was replicated three times and Replicas Analysis results 
are reported in Figure 6. In particular, the RMSD plot indicates that one replica 
does not reach the orthosteric site (Figure 6A, green line), whereas the others 
reach the same final RMSD value.  
 
Figure 6. Acid Ellagic-CK2 recognition pathway (A) Per Replica Ligand RMSD (B) Per 
Replica Pollicino Analysis (C) Per Replica IE Landscape (D) Per Replica cumulative IE. 
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The same conclusion arises from the investigation of the Pollicino analysis where 
the ligand pathway of the two replicas converge in proximity of the protein 
(Figure 6B, red and blue spheres).  
The Per Replica IE Landscape helps in explaining why the third replica 
does not reach the orthosteric site: as indicated by the green dots in Figure 5C 
the ligand reaches a different interaction site with an IE of -60 kcal/mol, a value 
close to the IE of the replicas that converge into in the orthosteric site (Figure 
6C, red and blue dots). This consideration is confirmed by the trend of the Per 
Replica Cumulative IE that highlights a more negative slope for the third replica 
(Figure 6D, green line), indicating a very strong interaction.  
 
SASP-GSTP1-1 recogni t ion pathway.   
During the SuMD simulation the SASP reaches the GSTP1-1 catalytic H 
site in less than 6 ns (Video S2). The IE landscape highlights the formation of 
the first protein-ligand stabilizing interaction when the ligand and protein H site 
distance is 15 Å (point a, Figure 7A and 7B). 
In this preliminary complex, SASP engages the Gly205 backbone oxygen 
in a hydrogen bond interaction through its sulfamide nitrogen atom and 
establishes an aromatic π-π stacking interaction between the salicylic moiety and 
Tyr108 (interactions corresponding to the first continues lines in the Protein-
Ligand Recognition Map, Figure 7C). This situation anticipates a ligand 
positional shift that allows the SASP salicylic carboxylate to approach the 
positively charged Arg13 side chain, while the benzene ring replaces the salicylic 
aromatic moiety in the π-π stacking interaction with Tyr108 (point b, Figure 7A). 
The energy stabilization of the complex increases and, after 8 ns of simulation, 
SASP proceeds toward a farther conformation, able to gain a more favourable 
electrostatic interaction geometry with Arg13 side chain, after the displacement 
of two water molecules from the solvation sphere of the positively charged 
residue. This new pose (point c, Figure 7A and Figure 7B) is retained until the 
end of SuMD simulation, with the exception of conformational changes 
occurring to thepyridylsulfamoyl moiety, able to fit in the hydrophobic pocket 
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delimited by Phe8, Val35 Trp38. During the SASP - GSTP1-1 recognition event 
GSH remain in the catalytic G site of the enzyme, not interacting with the 
inhibitor. Figure 7D highlights all the residues involved in the interaction with 
SASP during the SuMD simulations: the selective contacts towards only one 
enzymatic subunit, as well as the topologically restricted area interested, are well 
defined by the ribbon colorations. 
Considering the SASP crystallographic conformation as geometrical 
reference, the ligand RMSD analysis (Figure 7E) reaches a minimum after 15 ns 
of simulation (Figure 7F), before level out at a value of about 5 Å. Figure S2 
reports other ligand-protein interaction energy analysis. 
The Replicas Analysis (Figure S3) depicts a recognition event with no 
meta-stable binding sites and characterized by almost a univocal pathway. 
Nevertheless, in one replica, in the final complex SASP is rotated by 180° (as 
highlighted by the higher RMSD value) and loses the electrostatic stabilization 
between its salicylic moiety and Arg13 side chain.  
 
Benzen-1,2-dio l−PDRX5 recogni t ion pathway.   
The simulation was repeated on both monomeric and dimeric form 
yielding similar results. However, here we will focus on the dimeric form 
according to solution NMR studies, in which the authors stated the protein as 
dimer56. At the beginning of randomization step the fragment was placed at 78 Å 
from PDRX5 binding site (dcm(L-R)= 78 Å). As reported in figure 8A, 8B (point 
b) and 8C, after nearly 3 ns the fragment approaches the protein in a region 
located at around 30 Å from the primary binding site (Video S3).  
This meta-binding site lies in the opposite monomeric subunit with 
respect to the primary binding site and it is defined by residues Leu62, Lys63, 
Val69, and Val70. As shown by the IE landscape and the Pollicino Analysis 
(Figure 8A and 8B, respectively), this site engages the ligand with favorable 
interactions for a couple of nanoseconds. In particular, the formation of a 
hydrogen bond between the hydroxyl groups of catechol and the carbonyl 
moiety of the backbone amide of residue Lys95 stabilizes this conformation. 
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Figure 7 – SASP-GSTP1-1 recognition pathway. (A) IE Landscape (B) Pollicino 
Analysis (C) Ligand-Protein Recognition Map (D) Chimera contacts (E)  Ligand RMSD 
(F) Superimposition between SuMD endpoint conformation and X-ray binding mode. 
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After nearly 6 ns the fragment is released by this site and fluctuates to 
finally reach the primary binding site thought a series of molecular interaction, 
including residues (chronologically sorted): Glu91, Glu16, Glu18, Phe79 
belonging to the first monomer unit (SI figure S4). Finally, the fragment accesses 
to the binding site where fluctuates experimenting different conformations in 
accordance with its affinity in the millimolar range. The fluctuations of the 
fragment in the binding site are also evident in the Protein-Ligand Energy 
profiles, in which the energy wavers around the value of -20 kcal/mol (SI figure 
S4). During the fluctuation, the catechol enters in contact with most of the 
residue forming the site, in particular (sorted by number of molecular contacts 
during the trajectory): Thr146, Thr44, Arg127, Phe120, Leu116, Gly46 and 
Cys47 (Figure 8C, 8D). The main conformation observed corresponds to the 
crystallographic one, as reported in Figure 8E and 8F where the RMSD reaches a 
minimum value 0.69 Å at 17.3 ns.  
The simulation was repeated in three times randomizing the position of 
the ligand. The Replicas Analysis is reported in Figure S5. Briefly, in each replica 
the fragment reached the primary binding site experiencing the conformation 
reported in the crystallographic data with the best RMSD respectively of 1.12 
and 1.24 Å for the replica 2 and 3.  
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Figure 8 –Benzen-1,2-diol-PDRX5 recognition pathway. (A) IE Landscape (B) 
Pollicino Analysis (C) Ligand-Protein Recognition Map (D Chimera contacts. (E) 
Ligand RMSD (F) Superimposition between SuMD endpoint conformation and X-ray 
binding mode. 
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(S)-naproxen-HAS recogni t ion pathway.   
SuMD simulation was performed maintaining decanoic ligand in the IB 
site according the crystallographic geometries. (S)-naproxen was separated from 
HSA-decanoid acid complex by 32 Å from IB site (point a in Figure 9A and 9B). 
In the first SuMD step the ligand fluctuate till 50 Å from the IB site. As reported 
in Figure 9C after a couple of nanosecond the ligand approaches the first protein 
site in its trajectory by engaging Lys510 and Thr564 (Video S4). Shortly after, the 
ligand establishes a network of interaction for 1 ns (from 2.3 ns to 3.2) in a site 
located at around dcm(L-R)= 20 Å (point b in Figure A), defined by residues: 
Val116, Pro118, Val122, Thr133 and Phe134. Then, the Naproxen molecule 
approach a second, where it fluctuates for about 3 ns by establishing strong 
interaction with residues Leu115, Pro118, Lys137, and Ile142 (as also evident 
from Protein-Ligand Interaction energy in figure S6 in SI).  
This meta-binding site is located in front of the principal binding site to 
which is separated by the presence of a long extended loop (residue 106 to 119) 
that acts as a gate for the IB site. Finally after 6 ns, (S)-naproxen is able to pass 
behind the extended loop and reach the IB site (residues Leu115, Ile142, Phe157, 
Tyr161) as show by Figure 9B and 9E. Within the primary site, the ligand is able 
to place the methyl ether group in the proximity of Phe152 very similarly to the 
orientation of crystal structure. On the other hand, the naphthalene core and in 
particular the carboxylic group adopt a different orientation due to the presence 
of the extended loop. This different orientation abolishes the ionic interaction 
between the carboxyl group and the Arg112 observed in the crystallographic 
structure (Figure 9F). At the end of the simulation the RMSD fluctuates around 
5 Å, reaching the lowest value of 4.76 at 12.70 ns (Figure 9E and 9F).  
Interestingly, in the other replicas (Figure S7) the ligand reaches the IB 
site by approaching the extended loop from a different position and occupies a 
slightly different location in the vast IB site. This suggests the loop might have a 
crucial role in the recognition process (Figure S7). 
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Figure 9. (S)-naproxen-HAS recognition pathway. (A) IE Landscape (B) 
Pollicino Analysis (C) Ligand-Protein Recognition Map (D Chimera contacts.  
 (E) Ligand RMSD (F) Superimposition between SuMD endpoint conformation and X-
ray binding mode. 
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Transmembrane Systems  
(S)- f luoxet ine-LeuT recogni t ion pathway.   
The (S)-fluoxetine recognition pathway highlights, after 1 ns of SuMD 
simulation, a first electrostatic interaction between Asp 158 side chain and the 
ligand charged secondary amine group (Video S5). The energetic stabilization 
characterizing this complex corresponds to the IE landscape minimum reported 
in the Figure 10A, point a and Figure 10B. This preliminary complex is able to 
favor the ligand approach towards an inner pocket of LeuT, topologically 
defined by Tyr 471 and the aliphatic chains of Lys 474 and Glu 478, reciprocally 
involved in an ionic interaction. Hydrophobic contacts stabilize this 
intermolecular complex for about 2 ns, before a conformational change allows 
(S)-fluoxetine to establish a more favorable electrostatic interaction whit Glu 402 
side chain. This scenario anticipates the ligand repositioning inside an inner 
hydrophobic site, where the ligand engages for almost 7ns Tyr471, Trp406, 
Ile475 and Phe405 side chains in lipophilic interactions through its phenyl ring 
(point b, Figure 10A and Figure 10B). During the remaining simulation time, the 
inhibitor makes contacts with Ala319 (EL4) and the side chains of the key 
residues Asp404 and Arg30 (point c, Figure 10A and Figure 10B and continuous 
lines corresponding to the last 4ns of SuMD simulation in Figure 10C), both 
located at the protein extracellular gate and involved in a ionic lock that 
10terically obstructs the SSRIs binding site disclosed by LeuT crystallographic 
structure. Figure 10D summarizes all the amino acids involved in the SFX 
recognition event during the SuMD simulation.  
The RMSD plot (Figure 10E) outlines the inhibitor difficulty in 
reproducing the experimental pose (Figure 10F). Investigation on LeuT crystal 
structure without co-crystallized inhibitor reveale an alternative conformation of 
Arg30 side chain, and the absence of the gate ionic lock (Figure S12)57 : it is 
possible to speculate that the LeuT extracellular gate, during SuMD  simulation 
timescale, is able to remain in a stable conformation, previously induced by the 
inhibitor binding and retained even after the removal of the ligand during the 
system preparation for SuMD. 
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Replicas analysis (Figure S9) highlights two alternative recognition pathways 
through the extracellular vestibule, unable to enable SFX to reproduce the 
binding mode observed in the crystallographic complex and characterized by 
accentuated energy variations in proximity of the extracellular transporter gate.  
 
 
Figure 10. (S)-fluoxetin-LeuT recognition pathway. (A) IE Landscape (B) Pollicino 
Analysis (C) Ligand-Protein Recognition Map (D Chimera contacts.  
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Figure 10 (continuation). (E) Ligand RMSD (F) Superimposition between SuMD 
endpoint conformation and X-ray binding mode. 
 
NECA−hA2A AR recogni t ion pathway.   
NECA establishes the first stabilizing contacts with hA2A AR after about 
4ns of SuMD simulation (Video S6). During this initial scenario (point a, Figure 
11A and Figure 11B) the ligand approaches the protein topological structure 
defined by ECL2 N-terminus and the residues located at top of TM5 and TM6. 
More precisely, NECA engages Phe257 (6.59) side chain in a π-π stacking 
interaction through its purine scaffold and locates the N-ethylcarboxamido 
moiety towards a pocket delimited by Trp143 (ECL2), Pro173 (ECL2), and 
Asn175 (TM5) side chains, as highlighted by the first stripes in Figure 11C and 
the yellow and violet ribbon coloration in Figure 11D.  
This complex anticipates a repositioning that allows the ligand to reach a 
meta-stabile binding site, mainly characterized by a π-π stacking interaction with 
His264 (EL3) side chain, an hydrophobic contact in the direction of Met174 
(TM5) side chain, and an hydrogen bond interaction between its C2’ hydroxide 
group and Asn253 (TM6) (point b, Figure 11A and Figure 11B).  
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Figure 11. NECA-hA2A AR recognition pathway. (A) IE Landscape (B) Pollicino 
Analysis (C) Ligand-Protein Recognition Map (D) Chimera contacts (E) Ligand RMSD 
(F) Superimposition between SuMD endpoint conformation and X-ray binding mode. 
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During the time slot rising from 14 ns to 20 ns of SuMD simulation, the 
agonist reaches a deeper position inside the orthosteric binding site and explores 
different conformations (included a temporary anti-syn transition about the 
glycoside linkage), until engages Phe168 (ECL2) side chain in a π-π stacking 
interaction and Asn253 (TM6) side chain in hydrogen bond interactions through 
its exocyclic amine and the N7 position of the purine scaffold (point c, Figures 
11A and Figures 11B). This complex orientation (associated with the minimum 
RMSD value in Figure 11E, with respect to the NECA crystallographic 
conformation) is followed by an alternative stabilized conformation (point d, 
Figure 11A and Figure 11B) which involves also hydrophobic interactions with 
Leu249 (TM6), Leu85 (TM3) and Val84 (TM3).  
During the remaining SuMD simulation time, the protein-ligand complex 
geometry remain almost unaltered, with the exception of a reorientation of the 
N-ethylcarboxamidoribose moiety, pointing toward TM4, and the loss of the 
aromatic π-π interaction due to a conformational change occurring to Phe168 
(EL2) side chain. In Figure 10S are reported other ligand-protein energy 
interaction analysis. 
At the minimum RMSD value, NECA pyrimidine scaffold coincides with 
the crystallographic orientation, while the ribose moiety is oriented in an 
alternative conformation (Figure 11F).  
Replicas Analysis (Figure 11S) highlights also a different NECA 
recognition pathway, which involves residues located at the ECL2 and 
characterized by comparable energetic stabilizations.  
 
Conclus ion  
In the present work, we have demonstrated the general applicability of 
SuMD simulations using different types of proteins, including both globular and 
membrane proteins. Moreover, we have presented the SuMD-Analyzer tool that 
helps, also a non-expert user, in the analysis of the SuMD trajectories. Even if 
various other MD methods have also been used to characterize binding 
pathways, SuMD has the great advantage of being able to explore the ligand-
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protein approaching path in nanosecond simulation time scale. Furthermore, 
SuMD simulations enable the investigation of ligand-protein binding events 
independently from the starting position, chemical structure of the ligand, and 
also from its target binding affinity. As described for each key study, SuMD 
simulations are able to characterize multiple ligand-protein binding pathways 
identifying a variety of metastable intermediate states (meta-binding sites). These 
informations may be an interesting starting point for further argumentations 
regarding the pharmacological consequences of that specific ligand-protein 
recognition process. Moreover, it is worthy to underline that, contrary to 
expectations, not all SuMD trajectories converge to the structure of the complex 
obtained crystallographically. Indeed, there are several plausible reasons that may 
be argued to describe this particular unexpected aspect: a) the crystallographic 
pose of the ligand is not the only minimum of the potential energy surface 
described by the force field during the SuMD simulations; b) the crystallographic 
conformation of the protein in its bound state is remarkably different respect its 
apo-form. This could be interpreted as the sign of an important induce-fit 
process during the ligand recognition; and c) the boundary conditions that led to 
the formation of the crystallographic ligand-protein complex (solvent and co- 
solvent, pH, ionic strength, or temperature just as a few examples) are not well 
described during the SuMD simulations. This must always be kept in mind when 
any conjecture is made starting from the analysis of SuMD trajectories. Currently, 
a major effort is underway to estimate, from SuMD simulations, binding kinetics 
properties (in particular on-rate values) in approximate agreement with 
experimental measurements.  
Hopefully, the future of drug design will involve detailed characterization 
of not only the bound state but also the whole ligand–protein network of 
recognition pathways, including all metastable intermediate states (meta-binding 
sites). With such a complete understanding we hope expand our perspectives in 
several scientific areas from molecular pharmacology to drug discovery.  
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Abbreviations   
3D  three-dimensional  
CK2  caseine kinase 2  
CPU  central processing unit  
GPCRs  G protein-coupled receptors  
GPU   graphics processor unit 
GSTP1-1  P1-1 isoform of glutathione S-transferase  
hA2AAR  human A2A adenosine receptor  
HSA   human serum albumin  
IE   interaction energy  
Kd   equilibrium dissociation constant 
Koff   dissociation rate constants 
Kon   association rate constants  
LeuT  leucine transporter 
MD   molecular dynamics 
NECA   5'-N-ethylcarboxamidoadenosine  
PDB   protein data bank 
POPC   1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine 
PRDX5  eroxiredoxin 5  
RMSD   root-mean-square deviation 
SASP   sulphasalazine  
SuMD   supervised molecular dynamics  
 
 
 
 
 
 
 
 
  
 111 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
 
Bibliography 
 
1. Protein-Ligand Interactions: From Molecular Recognition to Drug 
Design; Böhm, H.-J., Schneider, G., Eds.; Methods and Principles in 
Medicinal Chemistry; Wiley-VCH Verlag GmbH & Co. KGaA: 
Weinheim, FRG, 2003. 
  
2. Pan, A. C.; Borhani, D. W.; Dror, R. O.; Shaw, D. E. Molecular 
Determinants of Drug– receptor Binding Kinetics. Drug Discov. Today 
2013, 18 (13–14), 667–673.  
 
3. Moro, S.; Hoffmann, C.; Jacobson, K. A. Role of the Extracellular Loops 
of G Protein- Coupled Receptors in Ligand Recognition: A Molecular 
Modeling Study of the Human P2Y1 Receptor. Biochemistry (Mosc.) 
1999, 38 (12), 3498–3507.  
 
4. Dror, R. O.; Jensen, M. Ø.; Borhani, D. W.; Shaw, D. E. Exploring 
Atomic Resolution Physiology on a Femtosecond to Millisecond 
Timescale Using Molecular Dynamics Simulations. J. Gen. Physiol. 2010, 
135 (6), 555–562. 
 
5.  Buch, I.; Giorgino, T.; De Fabritiis, G. Complete Reconstruction of an 
Enzyme-Inhibitor Binding Process by Molecular Dynamics Simulations. 
Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (25), 10184–10189.  
 
6. Johnston, J. M.; Filizola, M. Beyond Standard Molecular Dynamics: 
Investigating the Molecular Mechanisms of G Protein-Coupled Receptors 
with Enhanced Molecular Dynamics Methods. In G Protein-Coupled 
Receptors - Modeling and Simulation 796; 95–125, Springer Netherland, 
2014.  
 112 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
7. Sabbadin, D.; Moro, S. Supervised Molecular Dynamics (SuMD) as a 
Helpful Tool To Depict GPCR–Ligand Recognition Pathway in a 
Nanosecond Time Scale. J. Chem. Inf. Model. 2014, 54 (2), 372–376. 
 
8. Ciancetta, A.; Sabbadin, D.; Federico, S.; Spalluto, P.; Moro, S. Advances 
in Computational Techniques to Study GPCR-Ligand Recognition. In 
Trends in Pharmacol Sci (2015) in press DOI: 10.1016/j.tips.2015.08.006.  
 
9. Sabbadin, D.; Ciancetta, A.; Deganutti, G.; Cuzzolin, A.; Moro, S. 
Exploring the Recognition Pathway at the Human A2A Adenosine 
Receptor of the Endogenous Agonist Adenosine Using Supervised 
Molecular Dynamics Simulations. MedChemComm 2015, 6 (6), 1081–
1085.  
 
10. Deganutti, G.; Cuzzolin, A.; Ciancetta, A.; Moro, S. Understanding 
Allosteric Interactions in G Protein-Coupled Receptors Using Supervised 
Molecular Dynamics: A Prototype Study Analysing the Human A3 
Adenosine Receptor Positive Allosteric Modulator LUF6000. Bioorg. 
Med. Chem. 2015. 
 
11. Paoletta, S.; Sabbadin, D.; von Kügelgen, I.; Hinz, S.; Katritch, V.; 
Hoffmann, K.; Abdelrahman, A.; Straßburger, J.; Baqi, Y.; Zhao, Q.; 
Stevens, R. C.; Moro, S.; Müller, C. E.; Jacobson, K. A. Modeling Ligand 
Recognition at the P2Y12 Receptor in Light of X- Ray Structural 
Information. J. Comput. Aided Mol. Des. 2015, 29 (8), 737–756.  
 
12. Harvey, M. J.; Giupponi, G.; Fabritiis, G. D. ACEMD: Accelerating 
Biomolecular Dynamics in the Microsecond Time Scale. J. Chem. Theory 
Comput. 2009, 5 (6), 1632– 1639. 
 
 113 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
13. Case, D.; Babin, V.; Berryman, J.; Betz, R.; Cai, Q.; Cerutti, D.; Cheatham 
Iii, T.; Darden, T.; Duke, R.; Gohlke, H.; others. Amber14, Version 
AMBER14; Http://ambermd.org/ (accessed October 2015); University 
of California, San Francisco, 2014.  
 
14. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. 
Development and Testing of a General Amber Force Field. J. Comput. 
Chem. 2004, 25 (9), 1157–1174.  
 
15. MacKerell, A. D.; Banavali, N.; Foloppe, N. Development and Current 
Status of the CHARMM Force Field for Nucleic Acids. Biopolymers 
2000, 56 (4), 257–265.  
 
16. Vanommeslaeghe, K.; Raman, E. P.; MacKerell, A. D. Automation of the 
CHARMM General Force Field (CGenFF) II: Assignment of Bonded 
Parameters and Partial Atomic Charges. J. Chem. Inf. Model. 2012, 52 
(12), 3155–3168.  
 
17. Vanommeslaeghe, K.; MacKerell, A. D. Automation of the CHARMM 
General Force Field (CGenFF) I: Bond Perception and Atom Typing. J. 
Chem. Inf. Model. 2012, 52 (12), 3144–3154. 
 
18. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; 
Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. 
Nucleic Acids Res. 2000, 28 (1), 235–242. 
 
19.  CCG Inc. Molecular Operating Environment (MOE), 2014.09; 
Http://www.chemcomp.com (accessed October 2015).  
 
20. Labute, P. Protonate3D: Assignment of Ionization States and Hydrogen 
Coordinates to Macromolecular Structures. Proteins 2009, 75 (1), 187–
 114 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
205. Stewart, J. J. P. MOPAC2012, Version 2012; 
http://OpenMOPAC.net (accessed October 2015); Stewart 
Computational Chemistry: Colorado Springs, CO, USA, 2012.  
 
21. Stewart, J. J. P. Optimization of Parameters for Semiempirical Methods 
V: Modification of NDDO Approximations and Application to 70 
Elements. J. Mol. Model. 2007, 13 (12), 1173–1213. 
 
22. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; 
Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. 
A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; 
Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; 
Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; 
Nakai, H.; Vreven, T.; Montgomery, J. A.; Peralta, J. E.; Ogliaro, F.; 
Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; 
Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; 
Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; 
Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, 
R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; 
Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, 
G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; 
Farkas; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 
09, Revision B.01; Gaussian, Inc.: Wallingford, CT, 2009. (24). 
 
23. MacKerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. 
D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, 
D.; Kuchnir, L.; Kuczera, K.; Lau, F. T.; Mattos, C.; Michnick, S.; Ngo, 
T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, 
M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiórkiewicz- Kuczera, 
J.; Yin, D.; Karplus, M. All-Atom Empirical Potential for Molecular 
 115 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
Modeling and Dynamics Studies of Proteins. J. Phys. Chem. B 1998, 102 
(18), 3586–3616.  
  
24. Vanommeslaeghe, K.; MacKerell, A. D. Automation of the CHARMM 
General Force Field (CGenFF) I: Bond Perception and Atom Typing. J. 
Chem. Inf. Model. 2012, 52 (12), 3144–3154. 
 
25. Head-Gordon, M.; Pople, J. A.; Frisch, M. J. MP2 Energy Evaluation by 
Direct Methods. Chem. Phys. Lett. 1988, 153 (6), 503–506.  
 
26. Mayne, C. G.; Saam, J.; Schulten, K.; Tajkhorshid, E.; Gumbart, J. C. 
Rapid Parameterization of Small Molecules Using the Force Field Toolkit. 
J. Comput. Chem.2013, 34 (32), 2757–2770.  
 
27. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular 
Dynamics. J. Mol. Graph. 1996, 14 (1), 33–38, 27–28. 
 
28.  Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, 
C. Comparison of Multiple Amber Force Fields and Development of 
Improved Protein Backbone Parameters. Proteins 2006, 65 (3), 712–725. 
 
29. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, 
M. L. Comparison of Simple Potential Functions for Simulating Liquid 
Water. J. Chem. Phys. 1983, 79 (2), 926. 
 
30. Berendsen, H. J. C.; Postma, J. P. M.; Gunsteren, W. F. van; DiNola, A.; 
Haak, J. R. Molecular Dynamics with Coupling to an External Bath. J. 
Chem. Phys. 1984, 81 (8), 3684–3690. 
31. Loncharich, R. J.; Brooks, B. R.; Pastor, R. W. Langevin Dynamics of 
Peptides: The Frictional Dependence of Isomerization Rates of N-
Acetylalanyl-N’-Methylamide. Biopolymers 1992, 32 (5), 523–535.   
 116 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
 
32. Kräutler, V.; van Gunsteren, W. F.; Hünenberger, P. H. A Fast SHAKE 
Algorithm to Solve Distance Constraint Equations for Small Molecules in 
Molecular Dynamics Simulations. J. Comput. Chem. 2001, 22 (5), 501–
508.   
 
33. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, 
L. G. A Smooth Particle Mesh Ewald Method. J. Chem. Phys. 1995, 103 
(19), 8577–8593.   
 
34. Lomize, M. A.; Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. OPM: 
Orientations of Proteins in Membranes Database. Bioinforma. Oxf. Engl. 
2006, 22 (5), 623–625.   
 
35. Grubmüller, H.; Groll, V. Solvate, Version 1.0.1; 
Http://www.mpibpc.mpg.de/grubmueller/solvate (accessed October 
2015); 1996. Williams, T.; Kelley, C. Gnuplot 4.5: An Interactive Plotting 
Program, Version 4.5; Http://gnuplot.info (accessed October 2015).  
 
36. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, 
D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera--a Visualization System 
for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25 (13), 
1605–1612.  
 
37. Seeber, M.; Felline, A.; Raimondi, F.; Muff, S.; Friedman, R.; Rao, F.; 
Caflisch, A.; Fanelli, F. Wordom: A User-Friendly Program for the 
Analysis of Molecular Structures, Trajectories, and Free Energy Surfaces. 
J. Comput. Chem. 2011, 32 (6), 1183–1194.  
 
38. Cozza, G.; Bortolato, A.; Moro, S. How Druggable Is Protein Kinase 
CK2? Med. Res.Rev. 2010, 30 (3), 419–462.   
 117 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
 
39. Sekiguchi, Y.; Nakaniwa, T.; Kinoshita, T.; Nakanishi, I.; Kitaura, K.; 
Hirasawa, A.; Tsujimoto, G.; Tada, T. Structural Insight into Human 
CK2α in Complex with the Potent Inhibitor Ellagic Acid. Bioorg. Med. 
Chem. Lett. 2009, 19 (11), 2920–2923.  
 
40. Wilce, M. C.; Parker, M. W. Structure and Function of Glutathione S-
Transferases. Biochim. Biophys. Acta 1994, 1205 (1), 1–18.  
 
41. Laborde, E. Glutathione Transferases as Mediators of Signaling Pathways 
Involved in Cell Proliferation and Cell Death. Cell Death Differ. 2010, 17 
(9), 1373–1380.  
 
42. Oakley, A. J.; Bello, M. Lo; Nuccetelli, M.; Mazzetti, A. P.; Parker, M. W. 
The Ligandin (non-Substrate) Binding Site of Human Pi Class 
Glutathione Transferase Is Located in the Electrophile Binding Site (H-
Site). J. Mol. Biol. 1999, 291 (4), 913–926. 
 
43. Aguirre, C.; Brink, T. ten; Guichou, J.-F.; Cala, O.; Krimm, I. Comparing 
Binding Modes of Analogous Fragments Using NMR in Fragment-Based 
Drug Design: Application to PRDX5. PLOS ONE 2014, 9 (7), e102300. 
44. Declercq, J.-P.; Evrard, C.; Clippe, A.; Stricht, D. V.; Bernard, A.; 
Knoops, B. Crystal Structure of Human Peroxiredoxin 5, a Novel Type 
of Mammalian Peroxiredoxin at 1.5 Å resolution1. J. Mol. Biol. 2001, 311 
(4), 751–759.  
 
45. Shichita, T.; Hasegawa, E.; Kimura, A.; Morita, R.; Sakaguchi, R.; Takada, 
I.; Sekiya, T.; Ooboshi, H.; Kitazono, T.; Yanagawa, T.; Ishii, T.; 
Takahashi, H.; Mori, S.; Nishibori, M.; Kuroda, K.; Akira, S.; Miyake, K.; 
Yoshimura, A. Peroxiredoxin Family Proteins Are Key Initiators of Post-
Ischemic Inflammation in the Brain. Nat. Med. 2012, 18 (6), 911–917. 
 118 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
 
46. Sjöholm, I.; Ekman, B.; Kober, A.; Ljungstedt-Påhlman, I.; Seiving, B.; 
Sjödin, T. Binding of Drugs to Human Serum albumin:XI. The 
Specificity of Three Binding Sites as Studied with Albumin Immobilized 
in Microparticles. Mol. Pharmacol. 1979, 16 (3), 767– 777.  
 
47. Lejon, S.; Cramer, J. F.; Nordberg, P. Structural Basis for the Binding of 
Naproxen to Human Serum Albumin in the Presence of Fatty Acids and 
the GA Module. Acta Crystallograph. Sect. F Struct. Biol. Cryst. 
Commun. 2008, 64 (2), 64–69. 
 
48. Kanner, B. I.; Zomot, E. Sodium-Coupled Neurotransmitter 
Transporters. Chem. Rev. 2008, 108 (5), 1654–1668.  
 
49. Zhou, Z.; Zhen, J.; Karpowich, N. K.; Law, C. J.; Reith, M. E. A.; Wang, 
D.-N. Antidepressant Specificity of Serotonin Transporter Suggested by 
Three LeuT-SSRI Structures. Nat. Struct. Mol. Biol. 2009, 16 (6), 652–
657. 
 
50.  Jacobson, K. A.; Gao, Z.-G. Adenosine Receptors as Therapeutic 
Targets. Nat. Rev. Drug Discov. 2006, 5 (3), 247–264.  
 
51. Cooke, R. M.; Brown, A. J. H.; Marshall, F. H.; Mason, J. S. Structures of 
G Protein- Coupled Receptors Reveal New Opportunities for Drug 
Discovery. Drug Discov. Today 2015. 
 
52.  Sabbadin, D.; Ciancetta, A.; Deganutti, G.; Cuzzolin, A.; Moro, S. 
Exploring the Recognition Pathway at the Human A Adenosine Receptor 
of the Endogenous Agonist Adenosine Using Supervised Molecular 
Dynamics Simulations. Med Chem Commun 6,1081-1085, 2015.   
 119 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
53. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; 
Leslie, A. G. W.; Tate, C. G. Agonist-Bound Adenosine A2A Receptor 
Structures Reveal Common Features of GPCR Activation. Nature 2011, 
474 (7352), 521–525. 
 
54. Barelier, S.; Linard, D.; Pons, J.; Clippe, A.; Knoops, B.; Lancelin, J.-M.; 
Krimm, I. Discovery of Fragment Molecules That Bind the Human 
Peroxiredoxin 5 Active Site. PLoS ONE 2010, 5 (3), e9744. 
 
55. Krishnamurthy, H.; Gouaux, E. X-Ray Structures of LeuT in Substrate-
Free Outward- Open and Apo Inward-Open States. Nature 2012, 481 
(7382), 469–474. 
 
56.  Kober, A.; Sjöholm, I. The Binding Sites on Human Serum Albumin for 
Some Nonsteroidal Antiinflammatory Drugs. Mol. Pharmacol. 1980, 18 
(3), 421–426.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Cuzzolin	   A,	   Sturlese	  M,	   Deganutti	   G,	   Salmaso	   V,	   Sabbadin	   D,	   Ciancetta	  
A 	  Moro	  S 	  J	  Chem	  Inf	  Model	  56 	  687-­‐705	  (2016)	  
	  
	  
	  
	   	  
 
 
  
	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	   -­‐	   Sabbadin	   D,	   Ciancetta	   A,	   Deganutti	   G,	   Cuzzolin	   A,	  Moro	   S. 
MedChemComm	  6 	  1081-­‐1085	  (2015)	  
	  	  
	  
	  
	   	  
 
3.2 Exploring the recognition pathway at the human A2A 
adenosine receptor of the endogenous agonist adenosine 
using supervised molecular dynamics simulations. 
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Stefano Moro*  
 
Abstract 
Adenosine is a naturally occurring purine nucleoside that exerts a variety 
of important biological functions through the activation of four G protein-
coupled receptor (GPCR) isoforms, namely the A1, A2, A2B and A3 adenosine 
receptors (ARs). Recently, the X-ray structure of adenosine-bound hA2A AR has 
been solved, thus providing precious structural details on receptor recognition 
and activation mechanisms. To date, however, little is still known about the 
possible recognition pathway the endogenous agonist might go through while 
approaching the hA2A AR from the extracellular environment. In the present 
work, we report the adenosine-hA2A AR recognition pathway through the 
analysis of a series of Supervised Molecular Dynamics (SuMD) trajectories. 
Interestingly, a possible energetically stable meta-binding site has been detected 
and characterized.  
 
Introduction  
Adenosine is a naturally occurring purine nucleoside that forms primarily 
from the metabolism of adenosine triphosphate (ATP), both intracellularly and 
extracellularly1. Consequently, the extracellular levels of adenosine are regulated 
by its synthesis, metabolism, release and uptake1,2. Adenosine exerts pleiotropic 
functions throughout the body. In the central nervous system (CNS), the 
nucleoside plays important functions, such as modulation of neurotransmitter 
release, synaptic plasticity and neuroprotection in ischemic, hypoxic and 
oxidative stress events1,3,4. In addition, adenosine plays different roles in a large 
variety of tissues. In the cardiovascular system, adenosine produces either 
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vasoconstriction or vasodilation of veins and arteries. Moreover, adenosine 
regulates T cell proliferation and cytokine production, inhibits lipolysis and 
stimulates bronchoconstriction1,3,4.  
Adenosine mediates its biological effects by recognizing four G protein-
coupled receptor (GPCR) isoforms, namely the A1, A2A, A2B and A3 adenosine 
receptors (ARs). Each subtype has a unique pharmacological profile, tissue 
distribution and effector coupling1,4. Considering receptor sequence similarity, 
among the human ARs (hARs), the most similar are the A1 and A3 ARs (49% 
similarity), and the A2A and A2B ARs (59% similarity). Conversely, the A1, A2A 
and A3 ARs possess relatively high affinity for adenosine whereas the A2B AR 
shows relatively lower affinity for adenosine, as summarized in Table 1.  
Recently, the crystallographic structure of adenosine- bound hA2A AR has 
been solved (PDB code: 2YDO)5. Although this structural data is extremely 
precious to interpret both receptor recognition and activation mechanisms of the 
endogenous agonist, little is still known about the possible recognition pathway 
between adenosine coming from the extracellular environment and the hA2A AR 
embedded in the cytoplasmic membrane.  
 
Table 2 - Adenosine affinities at the four receptor subtypes 
 hA1 , Ki (nM) 
hA2A, Ki 
(nM) 
hA2Ba hA3 
Adnosine ca .  100  310 15,000 290 
a
 Data from functional studies. 
b ref. 4 
 
In this context, Supervised Molecular Dynamics (SuMD) has been 
recently presented as an alternative computational method that allows the 
exploration of ligand–receptor recognition pathway investigations on a 
nanosecond (ns) time scale6. In addition to speeding up the acquisition of the 
ligand–receptor recognition trajectory, this approach facilitates the identification 
and the structural characterization of multiple binding events (such as meta-
binding, allosteric, and orthosteric sites) by taking advantage of the all-atom MD 
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simulation accuracy of a GPCR–ligand com- plex embedded into an explicit 
lipid–water environment6.  
In the present study, in order to better understand how adenosine 
approaches the orthosteric binding site of the hA2A AR, its recognition pathway 
has been described through the analysis of a series of SuMD trajectories. 
Interestingly, a possible energetically stable meta-binding site has been detected 
and characterized. The meta-binding site concept was introduced several years 
ago to describe those binding events that chronologically anticipate the 
orthosteric binding event7.  
 
Results and discussion  
As anticipated, recently the crystallographic structure of adenosine-bound 
hA2A AR has been solved. The attempt to apply MD methodology to address the 
problem of ligand dissociation from its receptor is subjected to some limitations. 
First of all, ligand dissociation dynamics is usually a slow event in comparison to 
the timescales accessible to current simulation techniques and computer 
resources. This does not mean necessarily that the actual event of ligand 
dissociation takes so long, but it is clear that conformational sampling cannot be 
done effectively in a conventional MD simulation. On the other hand, the 
recognition process between a ligand and its receptor is a very rare event to 
describe at the molecular level and, even with the recent GPU-based computing 
resources, it is necessary to carry out classical molecular dynamics (MD) 
experiments on a long microsecond time scale6. For this reason, in order to 
better under- stand how adenosine approaches the orthosteric binding site of the 
hA2A AR, its recognition pathway was explored using a SuMD study (Video 1).  
In particular, following the ligand recognition pathway emerged by the analysis 
of SuMD trajectories (Fig. 1 and Video 1), the third extracellular loop (EL3) of 
hA2A AR plays an essential role in directing the agonist toward the orthosteric 
binding site. In particular, His264, Ala265, Pro266 (EL3) and Leu267 (7.32) (Fig. 
1, panel A) establish favourable hydrophobic contacts with the adenine core of 
adenosine. Such interactions orient the ribose ring towards the entrance of the 
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orthosteric binding site. The hydroxyl group in the C3' position of the ribose 
ring is engaged in a direct hydrogen bond interaction with Glu169 (EL2). Not 
surprisingly, the described extracellular site corresponds to the previously 
reported meta-binding site located in EL36,7, which enables high-potency hA2A 
AR antagonists, such as ZM 241385, 6-IJ2,6- dimethylpyridin-4-yl)-5-phenyl-
1,2,4-triazin-3-amine (T4G), and 4-IJ3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-
chlorophenol (T4E), to reach the orthosteric binding cleft from the extracellular 
vestibule. As already described, once the antagonists reach the orthosteric 
binding site, they adopt binding conformations that match the geometric 
positions observed in the corresponding X-ray structures6.  
By approaching the orthosteric binding site, adenosine explores receptor-
bound states that only partially overlap – RMSD < 3.5 Å – (Fig. 1, panel B–C) 
with the crystallographic bound conformation. In such conformational states, 
the ribose moiety explores the bottom part of the binding pocket ("ribose-
down" conformation) and is in close contact with Thr88 (3.36). Glu169 (EL2) 
and Asn53 (6.55) are involved in key polar interactions with the endo and 
exocyclic nitrogen atoms of the aromatic core. Hydrophobic interactions are 
established with Met174 (5.35), Met177 (5.38), Ala59 (2.57), Ala63 (2.61), Val84 
(3.32) and Ile160 (El2). In particular, Phe168 (EL2) is involved in π-stacking 
interaction with the adenine core.  
Notably, the role of several key residues (such as Thr88 (3.36), Phe168 
(EL2) and Met177 (5.38)) herein highlighted is consistent with the available 
mutagenesis data for agonist binding, which have been recently analysed and 
clarified by means of MD/FEP calculations8.  
As reported in Fig. 1, panel D–F, once inside the orthosteric site, 
adenosine dynamically flips between two different binding modes: the one above 
reported – the so-called “ribose-down” conformation – and the “ribose-up” 
conformation (Fig. 1, panel D) where the ribose moiety is directed towards the 
extracellular space. The hydroxyl group, attached at the C2' position of the 
ribose ring, establishes a hydrogen- bond interaction with Glu169 (EL2) and the 
exocyclic nitro- gen atom of the adenine ring interacts with the Ser67 (2.65) side 
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chain. The agonist aromatic ring is involved in a π-stacking interaction with 
Phe168 (EL2). Val84 (3.32), Ala63 (2.61) and Met174 (5.35) are responsible of 
the majority of non-polar ligand–receptor contacts.  
 
 
 
Figure 1 (Panel A to D) - Overview of multiple adenosine binding conformation inside 
the hA2A AR binding pocket generated from SuMD simulation trajectories in 
comparison with X-ray crystal structure, PDB ID: 2YDO (wheat sticks). Stick 
colouring scheme is based on simulation progression (time). Hydrogen atoms are not 
displayed, whereas hydrogen bond interactions are highlighted as yellow dashed lines. 
(Panel E and G) Overview of multiple discrete binding states that occur during ligand–
receptor recognition. Arrow colouring scheme is based on simulation progression 
(time). Receptor ribbon representation is viewed from the membrane side facing 
transmembrane domain 6 (TM6) and transmembrane domain 7 (TM7). (Panel F) 
Ligand−receptor interaction energy landscape for the nonbiased adenosine-hA2A AR 
recognition process. The most energetically stable binding conformations of adenosine 
inside the hA2A AR binding pocket are highlighted by arrow. Interaction energy values 
are expressed in kcal mol-1.  
 
Therefore, although the described ligand–receptor contacts provide 
sufficient energetic protein–ligand complex stabilization to reach the global 
protein–ligand interaction energy minimum (Fig. 1, panel F), the recognition of 
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the agonist is not accompanied by subsequent stabilization of the ligand 
conformation within the orthosteric site, as adenosine dynamically flips between 
the “ribose down” and “ribose up” binding modes (Fig. 1, panel E). Therefore, 
as also elucidated by a clustering analysis of the space explored by adenosine 
during the binding pathway, the agonist recognition process does not show the 
same behaviour of potent hA2A AR antagonists. The adenosine binding profile, 
instead, is more similar to the one observed for a weak binder such as caffeine 
(Fig. 1, panel F)6. Moreover, this peculiar conformational landscape along with 
the emerged major interaction sites, which anticipate the orthosteric binding site, 
is independent from ligand placement and orientation at the beginning of the 
SuMD simulation (Fig. 1, panel G).  
 
Experimental  
 
General   
The numbering of the amino acids follows the arbitrary scheme by 
Ballesteros and Weinstein: each amino acid identifier starts with a helix number, 
followed by the position relative to a reference residue among the most 
conserved amino acids in that helix, to which the number 50 is arbitrarily 
assigned9.  
Trajectory analysis and figure and video generation have been performed 
using several functionalities implemented by Visual Molecular Dynamics10, 
WORDOM11, the PyMOL Molecular Graphics System, Version 1.5.0.4 
Schrödinger, LLC (http://www.pymol.org/) and the Gnuplot graphic utility 
(http://www.gnuplot.info/). Ligand-hA2A AR interaction energies were 
calculated by extrapolating the non-bonded energy interaction term of 
CHARMM27 Force Field12 using NAMD13.  
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Computat ional  fac i l i t i e s   
All computations were performed on a hybrid CPU/GPU cluster. 
Molecular dynamics simulation has been performed with a 2 NVIDIA GTX 680 
and 3 NVIDIA GTX 780 GPU cluster engineered by Acellera14. 
  
Human A2A adenos ine receptor–l igand complex preparat ion  
The selected agonist-bound crystal structures (PDB IDs: 2YDO5) and the 
FASTA sequence of the hA2A AR (Uniprot ID: P29274) were retrieved from the 
RCSB PDB database15 (http://www.rcsb.org) and the UniProtKB/Swiss-
Prot16,17, respectively. The co-crystallized ligand structure was extracted from the 
orthosteric binding site and randomly placed in the space above the receptor, at 
least 40 Å away from protein atoms. Ionization states and hydrogen positions 
were assigned by using the MOE-sdwash utility (pH 7.0). The FASTA sequence 
was aligned, using BLAST (Blosum 62 matrix)18, with the template sequence. 
Backbone and conserved residue coordinates were copied from the template 
structure, whereas newly modelled regions and non-conserved residue side 
chains were modelled and energetically optimized by using CHARMM 27 force 
field12 until a r.m.s. of conjugate gradient <0.05 kcal mol-1 Å-1 was reached. 
Missing loop domains were constructed by the loop search method implemented 
in the Molecular Operating Environment (MOE, version 2012.10) program19 on 
the basis of the structure of compatible fragments found in the Protein Data 
Bank. N-terminal and C-terminal were deleted if their lengths exceeded those 
found in the crystallographic template. The “Protonate-3D” tool20 was used to 
appropriately assign ionization states and hydrogen positions to the build models. 
Then, the structures were subjected to energy minimization with CHARMM 27 
force field12 until the r.m.s. of conjugate gradient was <0.05 kcal mol-1 Å-1. 
Protein stereochemistry evaluation was then performed by employing several 
tools (Ramachandran and χ plots measure j/ψ and χ1/χ2 angles, clash contact 
reports) implemented in the MOE suite19.  
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Receptor membrane embedding and sys tem preparat ion  
Receptors were embedded in a 1-palmitoyl-2-oleoyl-sn-glycero-3 
phosphocholine (POPC) lipid bilayer (85 × 85 Å wide) and placed into the 
membrane according to the suggested orientation reported in the “Orientations 
of Proteins in Membranes (OPM)” database21 for the hA2A AR in a complex 
with the antagonist T4G (PDB ID: 2YDV7). Overlapping lipids (within 0.6 Å) 
were removed upon insertion of the protein. The prepared systems were 
solvated with TIP3P water22 using the program Solvate 1.023 and neutralized 
with Na+/Cl- counterions to a final concentration of 0.154 M. The total number 
of atoms per system was approximately 75,000. Membrane MD simulations were 
carried out on a GPU cluster with the ACEMD program using the CHARMM27 
Force Field18 and periodic boundary conditions. Initial parameters for the 
ligands were derived from the CHARMM General Force Field for organic 
molecules24,25. The system was equilibrated using a stepwise procedure. In the 
first stage, to reduce steric clashes due to the manual setting up of the 
membrane–receptor system, a 500 step conjugate-gradient minimization was 
performed. Then, to allow lipids to reach equilibrium and water molecules to 
diffuse into the protein cavity and to avoid ligand–receptor interaction in the 
equilibration phase, protein and ligand atoms were restrained for the first 8 ns by 
a force constant of 1 kcal mol-1 Å-2. Then side chains were set free to move, 
while gradually reducing the force constant to 0.1 kcal mol-1 Å-2 to the ligand and 
alpha carbon atoms up to 9 ns. Temperature was maintained at 298 K using a 
Langevin thermostat with a low damping constant of 1 ps-1, and the pressure 
was maintained at 1 atm using a Berendsen barostat. Bond lengths involving 
hydrogen atoms were constrained using the M-SHAKE algorithm26 with an 
integration time step of 2 fs. Harmonical constraints were then removed and 
Supervised MD was conducted in a NVT ensemble. Long-range Coulomb 
interactions were handled using the particle mesh Ewald summation method 
(PME)27 with grid size rounded to the approximate integer value of cell wall 
dimensions. A non-bonded cutoff distance of 9 Å with a switching distance of 
7.5 Å was used. In order to assess the biophysical validity of the built systems, 
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the average area per lipid headgroup (APL) and bilayer thickness measurements 
for each built system were measured using Grid-MAT-MD28. The corresponding 
calculated averaged area per lipid headgroup of the extracellular and intracellular 
leaflet during the production phase for all simulations was in agreement with the 
experimental values measured for 1-palmitoyl-2- oleoyl-sn-glycero-3-
phosphocholine (POPC) lipid bilayers29.  
 
Conclusions  
 
In the present work, we have carried out SuMD experiments to elucidate 
the recognition pathway of the naturally occurring purine nucleoside adenosine 
by the hA2A AR. The analysis of the SuMD trajectories revealed that residues 
located in the third extracellular loop play an essential role in orienting the ribose 
ring of agonist toward the entrance of the orthosteric site, thus representing a 
possible energetically stable meta-binding site.  
Our analysis has also revealed that, once the orthosteric site is reached, 
adenosine experiences a dynamic flip between two different binding modes: the 
"ribose-down" and the “ribose-up” conformation, with the ribose moiety 
pointing towards the intracellular and extracellular space, respectively. 
Consequently, the adenosine binding profile resulting from our analysis 
resembles that of a weak binder rather than the one previously observed for 
potent hA2A AR antagonists.  
Further work is underway in our lab to better elucidate the role of the 
meta-binding site that has been detected and characterized in this study. In 
particular, SuMD simulations with adenosine-hA2A AR 2:1 stoichiometry are 
currently under evaluation. Moreover, we are carrying out a comprehensive 
SuMD exploration of the recognition pathway of adenosine against all other 
adenosine receptor subtypes to clarify the experimental selectivity profile 
provided by the natural agonist.  
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3.3 Understanding allosteric interactions in G protein-
coupled receptors using Supervised Molecular Dynamics: a 
prototype study analysing the human A3 adenosine receptor 
positive allosteric modulator LUF6000. 
 
Giuseppe Deganutti, Alberto Cuzzolin, Antonella Ciancetta, Stefano Moro*  
 
Abstract  
The search for G protein-coupled receptors (GPCRs) allosteric 
modulators represents an active research field in medicinal chemistry. Allosteric 
modulators usually exert their activity only in the presence of the orthosteric 
ligand by binding to protein sites topographically different from the orthosteric 
cleft. They therefore offer potentially therapeutic advantages by selectively 
influencing tissue responses only when the endogenous agonist is present. The 
prediction of putative allosteric site location, however, is a challenging task. In 
facts, they are usually located in regions showing more structural variation 
among the family members. In the present work, we applied the recently 
developed Supervised Molecular Dynamics (SuMD) methodology to interpret at 
the molecular level the positive allosteric modulation mediated by LUF6000 
toward the human adenosine A3 receptor (hA3 AR). Our data suggest at least 
two possible mechanisms to explain the experimental data available. This study 
represent, to the best of our knowledge, the first case reported of an allosteric 
recognition mechanism depicted by means of molecular dynamics simulations.  
 
Introduction  
Besides the orthosteric site, which conventionally recognizes endogenous 
ligands, most G protein-coupled receptors (GPCRs) possess topographically 
distinct allosteric sites that can be recognized by small molecules and accessory 
cellular proteins. Pharmacologically speaking, an allosteric modulator does not 
have any activity by itself, thus needing the orthosteric binder to exhibit its 
action. Although the modulatory character of allosteric binders is not always 
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clear-cut, true allosteric modulators increase or decrease the action of an agonist 
or an antagonist recognising the allosteric site(s) on the receptor. In facts, ligand 
binding to allosteric sites promotes a conformational reorganization in the 
GPCR that can alter orthosteric ligand affinity and/or efficacy. Although an 
allosteric modulator may not possess efficacy by itself, it can provide a powerful 
therapeutic advantage over orthosteric ligands, as they selectively influence tissue 
responses only when the endogenous agonist is present. Consequently, allosteric 
modulation of GPCRs has stimulated an intensive identification campaign for 
new classes of hit-candidates different from conventional agonists and 
antagonists. This has been the subject of several recent reviews1–3. 
However, natural allosteric sites are very difficult to identify because they 
are usually located far from the orthosteric sites. Moreover, allosteric sites resides 
in regions of the receptor that show more structural variation among family 
members and, consequently, this implies a general lack of success in predicting 
the locations of potential binding regions. Albeit the crystallographic structure of 
the M2 receptor simultaneously bound to the orthosteric agonist iperoxo and the 
positive allosteric modulator LY2119620 has been recently reported4, little is 
known about the possible allosteric control regarding the activation mechanism 
of other GPCRs.  
Within this framework, we have recently reported on an alternative 
computational method – the Supervised Molecular Dynamics (SuMD) – that 
allows to investigate the ligand– receptor recognition pathway in a nanosecond 
(ns) time scale5. In addition to speeding up the acquisition of the ligand–receptor 
recognition trajectory, this approach facilitates the identification and the 
structural characterization of multiple binding events (such as meta-binding, 
allosteric, and orthosteric sites) by taking advantage of the all-atom MD 
simulations accuracy of GPCR– ligand complexes embedded into explicit lipid–
water environment5.  
Interestingly, adenosine receptors (ARs) were among the first GPCRs 
discovered to be allosterically regulated and, in particular, allosteric enhancers for 
A1 and A3 ARs have been widely investigated1,2,6. Among the most interesting 
 137 	   SCIENTIFIC	  PUBLICATIONS	   	  
	   	  
	   Published	  -­‐	  Deganutti	  G,	  Cuzzolin	  A,	  Ciancetta	  A,	  Moro	  S.	  Biorg	  Med	  Chem.	  23,	  4065-­‐
4071	  (2015)	  	  
	  
	  
	  
	   	  
allosteric enhancers for the A3 AR, N-(3,4-dichlorophenyl)-2-cyclohexyl- 1H-
imidazo[4,5-c]quinolin-4-amine (LUF6000, see Fig. 1) has been deeply 
characterized7,8. LUF6000 potentiates the maximum efficacy of the agonist Cl-
IB-MECA by 45–50%, enhances agonist efficacy in functional assays and 
decreases the agonist dissociation rate without influencing agonist potency. 
Moreover, LUF6000 has been reported to act as allosteric enhancer of the 
maximal effect exerted by structurally diverse agonists at the A3 AR, being more 
effective for low-efficacy than for high-efficacy agonists.  
Very recently, in vivo studies have reported the ability of LUF6000 to act 
as allosteric modulator of rat and mice A3 ARs by allowing the endogenous 
ligand adenosine to bind to the receptor with higher affinity9.  
With the aim to interpret at the molecular level the positive allosterism 
mediated by LUF6000 toward the human A3 AR (hA3 AR), possible recognition 
pathways have been explored by performing SuMD simulations in the absence 
and in presence of the natural agonist adenosine (Fig. 1). Interestingly, our 
results suggest two possible mechanisms by which LUF6000 might exert its 
positive allosteric modulator effects: according to the outcomes of our 
simulations, the ligand might either induce a loop rearrangement that stabilizes 
agonist placement into the orthosteric site, or form a ternary complex with the 
agonist bound receptor state, thus acting as orthosteric pocket cap.  
 
 
Figure 1- Structures of the endogenous hA3 AR agonist adenosine (left) and the positive 
allosteric modulator LUF6000 (right). 
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SuMD Simulations 
  
LUF6000-hA3 AR recogni t ion mechanism.  
The imidazoquinolinamine allosteric modulator LUF6000 enhances 
agonist efficacy in functional assays and decreases agonist dissociation rate 
without influencing agonist potency7,8. Besides, LUF6000 presents a weak 
antagonist activity (ca. 45% inhibition at 10 µM)7. To explore LUF6000 attitude 
to recognize the orthosteric binding site of the hA3 AR, we analysed its 
recognition pathway by performing SuMD experiments.  
During the SuMD simulations, LUF6000 reached the orthosteric binding 
site in less than 20 ns. The corresponding energy landscape (Fig. 2A) highlights 
two major interaction sites (a and b). Prior reaching the orthosteric site, 
LUF6000 interacts with residues located in a region between the second and 
third extracellular loops (EL2 and EL3, respectively). Met151 (EL3), Thr154 
(EL2), Met174 (5.35) side chains and the aliphatic portion of Arg173 (EL2) 
establish hydrophobic contacts with the imidazoloquinoline core of LUF6000, 
whereas the ligand exocyclic nitrogen atom is involved in a hydrogen bond 
interaction with the backbone of Lys152 (EL2) (a in Fig. 2A, Fig. 2B, Video S1). 
While reaching the orthosteric site, the Val169 (EL2) side chain facilitates ligand 
reorientation providing favourable hydrophobic contacts. The most stable 
conformation observed (b Fig. 2A, Fig. 2C, Video S1) is characterized by 
hydrophobic contacts with Phe168 (EL2), Met174 (5.35), Leu246 (6.51), Leu264 
(7.35), Leu268 (7.39) and Trp243 (6.48), whereas Asn250 (6.55) is engaged in a 
hydrogen bond with the exocyclic nitrogen of the ligand. At the maximum 
energetic stabilization, the formed complex is characterized by energetic values 
of about -50 kcal/mol, a value previously observed for weak ARs binders. This 
is consistent with the LUF6000 antagonist activity observed through functional 
assays at the hA3 AR8. 
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Figure 2. (A) Interaction Energy landscape for the recognition pattern of LUF6000 by 
the hA3 AR.(B) LUF6000 binding mode in the meta-binding site.(C) LUF6000 binding 
mode in the orthosteric binding site. Ligand is displayed as orange stick, side chains of 
residues interacting through hydrogen bond or π-π stacking are depicted as grey stick, 
whereas side chains of residues interacting through hydrophobic contacts are rendered 
as coloured surfaces. 
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Adenosine-hA3 AR recogni t ion mechanism  
Recently, the crystallographic structure of adenosine in complex with the 
hA2A AR has been solved10. This structural piece of information aid elucidating 
both the recognition and activation mechanisms of the ARs by their endogenous 
agonist adenosine. Although in principle the interaction pattern of the 
adenosine-hA2A AR complex can be transferred to the other ARs subtypes, in 
order to better understand how adenosine approaches the orthosteric binding 
site of the hA3 AR, its recognition pathway as described by the obtained SuMD 
trajectories has been analyzed.  
In our SuMD experiments, adenosine reached the orthosteric binding site 
in less than 20 ns. The corresponding energy landscape is reported in Fig. 3A. 
During the recognition pathway (Video S2), EL3 engages the ligand ribose 
moiety in favourable hydrogen bonds mainly through Val259 (EL3) and Gln261 
(EL2) backbone atoms (b in Fig. 3A, Fig. 3B). This situation anticipates a change 
of adenosine orientation, triggered by hydrophobic contacts between the ligand 
purine core and Leu264 (7.35), Ile268 (7.39), Ile253 (6.58), and Ile249 (6.54) side 
chains. Once the orthosteric pocket is reached, adenosine interacts with the side 
chain of Trp185 (5.46), Leu246 (6.51) and conserved residues Asn250 (6.55), 
Phe168 (EL2), Trp243 (6.48), Ile268 (7.39) (Fig. 3C, Video S2). As already 
observed for adenosine recognition pathway by the hA2A AR11, the agonist 
explores different conformational states once inside the pocket. In particular, 
adenosine experiences a dynamic flip between two different binding modes: the 
above described "ribose-down" and the "ribose-up" conformation, with the 
ribose moiety pointing towards the intracellular and extracellular space, 
respectively. The ribose down conformation (b in Fig. 3A, Fig. S1) is 
characterized by additional electrostatic interactions with Glu19 (1.39) and Ser73 
(2.65) and represents the most energetically stable ligand-receptor complex 
observed in the analysed trajectories.  
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LUF6000-hA3 AR (in complex with adenos ine)  re cogni t ion mechanism  
With the aim to reproduce the experimental conditions that allow to 
measure LUF6000 PAM activity, SuMD simulations were performed considering 
the hA3 AR receptor in complex with adenosine. LUF6000 was randomly placed 
60 Å at least away from the barycentre of the orthosteric binding site. The 
starting adenosine-hA3 AR complex was extracted from the previously described 
SuMD trajectory, and selected on the basis of its similarity with the X-Ray 
crystallographic conformation observed for the complex with the hA2A AR10.  
The LUF6000 recognition energy landscape is reported in Fig. 4A. The 
pathway described by the SuMD trajectories highlights three main situations: i) 
LUF6000 not interacting with the adenosine-hA3 AR complex (point a in 
Fig.4A); ii) LUF6000 interacting with a meta-binding site (b in Fig. 4A); and iii) 
LUF6000 interacting with the orthosteric pocket (c in Fig. 4A). 
Moreover, during the SuMD simulations, the interaction energy between 
adenosine and the hA3 AR has been computed (Fig. 4B). The endogenous 
agonist reaches a stability maximum approximately after 10 ns of simulation 
(point B in Fig. 4B), which correspond to LUF6000-hA3 AR meta binding site 
complex formation. The ligand approaches EL2 (Fig. 5A) by recruiting Tyr157 
(EL2) and His158 (EL2) side chains, and establishing contacts with Arg173 
(EL2), Met174 (5.35), Ile253 (6.58), Tyr254 (6.59) (Fig. 4B, Video S3). This loop 
rearrangement is accompanied by conformational changes in residues located 
farther in EL2, included Phe168 (EL2), that loses the capability of stabilizing 
adenosine through π-π stacking interactions. As a consequence, adenosine 
moves deeper in the orthosteric pocket (Fig. S2) and establishes favourable 
interactions with Leu246 (6.51), Trp243 (6.48), Ser247 (6.52), and Thr94 (3.36). 
The overall protein conformational and adenosine positional changes that occur 
after the interaction between LUF6000 and the hA3 AR EL2 (i.e. system 
evolution from point a to point b) are reported in Fig. S3.  
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Figure 3. (A) Interaction Energy landscape for the recognition pattern of adenosine by 
the hA3 AR.(B) Adenosine binding mode in the meta-binding site.(C) Adenosine 
binding mode in the orhtosteric binding site. Ligand is displayed as tan stick, side 
chains of residues interacting through hydrogen bond or π-π stacking are depicted as 
grey stick, whereas side chains of residues interacting through hydrophobic contacts are 
rendered as coloured surfaces 
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Figure 4. (A) Interaction Energy landscape for the recognition pattern of LUF6000 by 
the hA3 AR-adenosine complex. (B) hA3 AR-adenosine interaction energy. 
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Once the complex with the meta binding site is formed, approximately 
after 14 ns of simulations, LUF6000 moves to establish hydrophobic interactions 
with Tyr254 (6.59), Met174 (5.35), Val169 (EL2) and Ile253 (6.58), located at the 
top of orthosteric binding site. This allows the ligand to directly interact with 
adenosine. Simultaneously, the previously evidenced π-π stacking interaction 
between adenosine and Phe168 (EL2) is restored. In the tertiary complex just 
formed, the energy interaction between adenosine and the hA3 AR is stabilized 
at values slightly lower than the starting complex, with the exception of a 
transitory stabilization after 21 ns (C in Fig. 4B, Fig. 5B). LUF6000 is therefore 
able to stabilize the interaction energy between adenosine and the hA3 AR and to 
lock the agonist inside the orthosteric pocket for the remaining simulation time. 
A similar behaviour has been observed also for the tertiary complex formed with 
a LUF6000 close analogue LUF6069 (See Supplementary Information, Fig. S4-
S5 and Video S4). 
 
Conclusion  
In the present work, we have utilized SuMD5, a computational approach 
we have recently developed, with the aim to characterize and rationalize the 
activity of LUF6000, a hA3 AR PAM, at a molecular level. We have analysed the 
ligand-receptor recognition pattern, both for LUF6000 and the endogenous 
agonist adenosine separately and also considering the recognition pathway of the 
PAM by the hA3 AR in complex with adenosine. This represents, to date, the 
first case reported of an allosteric mechanism investigated by means of MD 
simulations.  
Our results have highlighted that LUF6000 is able to establish favourable 
interactions with conserved residues located in the orthosteric binding site of the 
hA3 AR, consistently with the experimentally observed weak inhibitor activity at 
this receptor subtype. The analysis of the interaction pathway of the endogenous 
agonist adenosine suggests a key role played by residues located in the EL2 in 
engaging the agonist and energetically promoting its approach to the orthosteric 
pocket.  
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The inspection of the interaction pathway obtained by simulating 
LUF6000 approaching the hA3 AR in complex with the endogenous agonist 
adenosine suggests two possible mechanisms to explain the experimentally 
observed positive allosteric modulation7,8. According to our analysis, the ligand 
could: i) trigger conformational changes in the EL2 that would enable the 
agonist to form more energetically favourable interactions with residues located 
deeper in the orthosteric binding site; ii) establish a ternary complex with the 
agonist and the receptor, thus acting as orthosteric pocket cap.  
 
Figure 5. (A) LUF6000 binding mode in the hA3 AR meta-binding site.(B) LUF6000 
binding mode in the hA3 AR orthosteric binding site occupied by adenosine. LUF6000 
and adenosine are displayed as orange and tan stick, respectively. Side chains of 
residues interacting through hydrogen bond or π-π stacking are depicted as grey stick, 
whereas side chains of residues interacting through hydrophobic contacts are rendered 
as coloured surfaces. 
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The mutagenesis data available to date12 apparently confute the first hypothesis, 
as it has been reported that the mutation of some residues located in the upper 
region of the receptor does not affect the allosteric activity of the 
imidazoquinoline compound DU124183 and the pyridinylisoquinoline 
compound VUF545510. However, it is well accepted that a PAM activity is 
strictly depending on the structure of the agonist considered to perform the 
experiments. 
 
Experimental Section  
 
General   
All computations were performed on a hybrid CPU/GPU cluster. 
Molecular dynamics simulations have been performed with GPU cluster 
equipped with 3 NVIDIA GTX 780 and 3 NVIDIA GTX 980. 
Trajectory analysis, Figures and videos generation have been performed 
using several functionalities implemented by Visual Molecular Dynamics13, 
WORDOM14, the PyMOL Molecular Graphics System, Version 1.5.0.4 
Schrödinger, LLC (http://www.pymol.org/) and the Gnuplot graphic utility 
(http://www.gnuplot.info/). Ligand-hA3 AR interaction energies were calculated 
extrapolating the non-bonded energy interaction term of CHARMM27 Force 
Field15 using NAMD16. All molecular dynamics simulations have been carried 
out using ACEMD engine (http://www.acellera.com/).  
The numbering of the amino acids follows the arbitrary scheme proposed 
by Ballesteros and Weinstein17: each amino acid identifier starts with the helix 
number (1-7), followed by a dot and the position relative to a reference residue 
among the most conserved amino acids in that helix, to which the number 50 is 
arbitrarily assigned.  
 
Homology Model  o f  hA3 AR  
As, to date, no crystallographic information about the hA3 AR is available, 
we used a previously build homology model deposited in our web platform 
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dedicated to ARs, Adenosiland18,19. In particular, among all the currently 
available crystallographic structures of the hA2A AR we selected the model built 
upon the complex with the endogenous agonist adenosine (PDB code: 2YDO, 
3.00 Å resolution)10.  
 
Receptor membrane embedding and sys tem preparat ion.   
Receptors were embedded in a 1-palmitoyl-2-oleoyl-sn- glycero-3-
phosphocholine (POPC) lipid bilayer (85x95 Å wide) and placed into the 
membrane according to the suggested orientation reported in the “Orientations 
of Proteins in Membranes (OPM)” database20 for the hA2A AR in complex with 
the endogenous agonist adenosine (PDB ID: 2YDO )10. Overlapping lipids 
(within 0.6 Å) were removed upon insertion of the protein. The prepared 
systems were solvated with TIP3P water21 using the program Solvate 1.022 and 
neutralized by Na+/Cl- counter-ions to a final concentration of 0.154 M. The 
total number of atoms per system was approximately 110000. Membrane MD 
simulations were carried out on a GPU cluster with the ACEMD program using 
the CHARMM27 Force Field15 and periodic boundaries conditions. Initial 
parameters for the ligands were derived from the CHARMM General Force 
Field for organic molecules. The system was equilibrated using a stepwise 
procedure. In the first stage, to reduce steric clashes due to the manual setting up 
of the membrane-receptor system, a 2500 steps conjugate-gradient minimization 
was performed. Then, to allow lipids to reach equilibrium, water molecules to 
diffuse into the protein cavity and to avoid ligand-receptor interaction in the 
equilibration phase, protein and ligand atoms were restrained for the first 8 ns by 
a force constant of 1 kcal/mol•Å2. Then, force constant was gradually reduced 
to 0.1 kcal/mol•Å2 for the next 9 ns. Temperature was maintained at 298 K 
using a Langevin thermostat with a low damping constant of 1 ps-1 and the 
pressure was maintained at 1 atm using a Berendensen barostat. Bond lengths 
involving hydrogen atoms were constrained using the M-SHAKE algorithm23 
with an integration timestep of 2 fs.  
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SuMD simulat ions  
After the equilibration procedure, harmonical constraints were removed 
and SuMD simulations were conducted in a NVT ensemble. As previously 
described, the supervision of the trajectory is perpetuated until ligand-receptor 
distance is lower than 5 Å without introducing bias to the simulations. Long-
range Coulomb interactions were handled using the particle mesh Ewald 
summation method (PME)24 with grid size rounded to the approximate integer 
value of cell wall dimensions. A non-bonded cut-off distance of 9 Å with a 
switching distance of 7.5 Å was used. Ligand parametrization procedure and 
methodological insights on the quantitative estimate of the electrostatic and 
hydrophobic occurring ligand-protein interaction maps have been reported 
previously5.  
 
Abbreviations 
 ARs   adenosine receptors 
 ATP   adenosine triphosphate 
 hA3AR   human A3 adenosine receptor 
 EL2  second extracellular loop 
 EL3   third extracellular loop 
 LUF6000  N-(3,4-dichlorophenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-
amine 
 LUF6096  N-{2-[(3,4- dichlorophenyl)amino]quinolin-4-
yl}cyclohexanecarboxamide 
GPCRs   G protein-coupled receptors 
GPU   graphics processing unit 
PAM   positive allosteric modulator 
RMSD  root mean square deviation 
SAR   structure-affinity relationship; 
TM   transmembrane; ZM 241385, 4-[2- [7-amino-2-(2-furyl)-1,2,4-
triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethylphenol.  
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3.4 New Trends in Inspecting GPCR-ligand Recognition 
Process: the Contribution of the Molecular Modeling Section 
(MMS) at the University of Padova. 
 
Antonella Ciancetta, Alberto Cuzzolin, Giuseppe Deganutti, Mattia Sturlese, Veronica 
Salmaso, Andrea Cristiani, Davide Sabbadin and Stefano Moro*[a] 
 
Abstract  
In this review, we present a survey of the recent advances carried out by 
our research groups in the field of ligand-GPCRs recognition process 
simulations recently implemented at the Molecular Modeling Section (MMS) of 
the University of Padova. We briefly describe a platform of tools we have tuned 
to aid the identification of novel GPCRs binders and the better understanding of 
their binding mechanisms, based on two extensively used computational 
techniques such as molecular docking and MD simulations. The developed 
methodologies encompass: (i) the selection of suitable protocols for docking 
studies, (ii) the exploration of the dynamical evolution of ligand-protein 
interaction networks, (iii) the detailed investigation of the role of water 
molecules upon ligand binding, and (iv) a glance at the way the ligand might go 
through prior reaching the binding site. 
 
Introduction 
Today, it is largely recognized that G protein-coupled receptors (GPCRs) 
represent the largest family of surface receptors with more than 800 members in 
humans.1 They respond to different extracellular stimuli ranging from small 
molecules to lipids, peptides, proteins, and even light.2 
The binding event triggers the activation of cytoplasmic heterotrimeric 
GTP binding proteins (G proteins) and mediates the signal transduction through 
the modulation of several downstream effectors. The participation of GPCRs in 
numerous physio-pathological processes entails a potential role for their 
modulation by agonist, antagonists and inverse agonists in the treatment of 
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several diseases, including cardiovascular and mental disorders,3 cancer,4 and 
viral infections.5 Nowadays, about more than 50% of the drugs in clinical use 
targets a GPCR.6 
According to the GRAFS classification,7 human GPCRs are commonly 
grouped into five main classes: Glutamate (Class C), Rhodopsin (Class A), 
Adhesion (Class B), Secretin (Class B), and Frizzled/Taste2 (Class F). From a 
structural point of view, all members share a common architecture represented 
by seven membrane-spanning helices connected by three intracellular and three 
extracellular loops with the N-Term domain exposed toward the extracellular 
side.  
The insertion into the cell membrane along with receptors dynamism 
have hampered for long time the structural determination of GPCRs by X-ray 
crystallography. To overcome these limitations, several techniques have been 
developed: the use of fusion proteins such as T4 lysozyme or apocytochrome,8,9 
complexation with antibody fragments,10 and the receptor thermostabilization 
through systematic scanning mutagenesis.11 The advances in protein engineering 
and crystallography have represented a breakthrough for the research focused on 
GPCRs and yielded numerous X-ray structures.12 The availability of ligand-
bound three-dimensional structures provides invaluable insights to understand 
GPCRs function and pharmacology and enables the application of structure-
based drug design approaches to aid the discovery of novel candidates with 
improved pharmacological profiles.13 In particular, molecular dynamics (MD) 
simulations have become a helpful complement for the study of GPCRs 
biophysics and molecular pharmacology, by enriching our understanding of, 
among other aspects, ligand-receptor interaction and ligand-subtype 
selectivity.14,15 In addition, the recent exploitation of the commodity, graphics 
processing units (GPUs), a technology firstly designed to improve video game 
performances, in the molecular modeling field represents an important step 
forward for the simulation of GPCRs in explicit lipid-water environments within 
a reasonable computation time.16 In this paper, we briefly survey the recent 
advances carried out by our research groups in the field of ligand-GPCRs 
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recognition process simulations.17 Following the description of the tools we have 
developed to aid the identification of novel binders of GPCRs binders and the 
better understanding of their binding mechanisms, we will discuss their use in 
a case study: the comparison between ZM 241385 (4-(2-(7-Amino-2-(furan-2-yl)-
[1,2,4]triazolo[2,3-a][1,5-a][1,3,5]triazin-5-yl-amino)ethyl) phenol) and caffeine, a 
strong and weak human Adenosine 2A Receptor (hA2A AR) antagonists, 
respectively. 
 
Methods 
 
Docking Protoco ls  Validat ion:  the “Qual i ty  Descr iptors”   
The availability of ligand-bound crystal structures enables to perform 
docking simulations to rationalize structure-activity relationships of known 
binders or to conduct virtual screening campaigns to identify novel candidates. It 
is highly recommended to assess the performances of a docking protocol in 
reproducing the available experimental data prior to applying it. This procedure 
is best known as benchmark study. We have recently developed a pipeline that 
allows a fast graphical evaluation of different docking protocols, based on two 
newly defined quality descriptors: the “Protocol Score” and the “Interaction 
Energy Map” (IEM).18,19 
The “Protocol Score” is a RMSD based descriptor that assigns a 0–3 
score to each docking protocol according to the following criteria: (i) if the 
protocol returns either a RMSDave value lower than the crystal structure 
resolution (R) or generates at least 10 (out of 20) conformations having 
RMSD<R, a score 1 is assigned; (ii) if a protocol satisfies both the above 
mentioned requirements, a score 2 is assigned; (iii) if a protocol satisfies none of 
the above mentioned requirements, a score 0 is assigned. Moreover, a score 3 is 
conferred to the best protocols, i.e. those returning at the same time the lowest 
RMSDave value and the highest number of conformers with a RMSD<R. The 
scores are then converted in a color code and the data visualized as a colored 
map (Figure 1A): protocols corresponding to white and light green spots are not 
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suitable for the system under consideration, dark green spots highlight good 
protocols, whereas blue spots identify the best among the tested ones. 
The IEMs are based on the analysis of ligand-protein interactions and are 
derived as follows. Firstly, per residue electrostatic and hydrophobic 
contributions to the interaction energy (denoted IEele and IEhyd, respectively) 
are computed for residues surrounding the binding site or known to play a role 
in the binding. The analysis is performed for both the crystallographic binding 
modes and the docking poses. These pieces of information are then graphically 
transferred into heat-like maps reporting the key residues involved in the binding 
with the considered ligands along with a color code reflecting the quantitative 
estimate of the occurring interactions (the more intense the color, the stronger 
the interaction). The comparison is therefore based on the quality of the 
interactions in terms of number of established interactions and their relative 
strength among the X-Ray binding mode and the generated docking poses 
(Figure 1B).  
The main advantage of the proposed pipeline resides in the full 
automation of the benchmark procedure: the user is provided with pre-compiled 
input files for several docking programs, thus minimizing the required expertise 
to carry out the benchmark study. To this aim, the results are presented as easy 
to interpret colored maps enabling a fast graphical inspection of large amount of 
data. The results are analyzed on the basis of the above described quality 
descriptors. 
 
Binding Modes Inspec t ion:  the Dynamic Scor ing Funct ion (DSF) 
The docking approach suffers from several limitations.20 Although is a 
valuable method to get insights on the final stage of ligand-protein recognition, it 
lacks the description of two fundamental aspects that might play a significant 
role in ligand binding: water molecules mediated interactions and protein 
flexibility. To complete the description provided by the docking method with 
such contributions, we have recently developed the “dynamic scoring 
function”(DSF), an approach that enables to follow the dynamical evolution of a 
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docking pose in a realistic environment, i.e.the solvated membrane embedded 
ligand-protein complex.[21] The DSF provides a dynamic estimate of both the 
ligand position and the strength of the interaction network while accounting for 
the interplay of water molecules and protein side-chains flexibility. The 
procedure envisages the dynamic selection of residues within a range of 4.5 Å 
from the ligand during the MD simulation, starting from a previously obtained 
docking pose. The DSF is the cumulative sum of electrostatic and hydrophobic 
contributions to ligand-protein interaction (DSFele and DSFhyd, respectively) and 
is calculated at frames extracted every 100 ps as follows:  
 
DSFele = IEelet=0
n
∑          (1) 
DSFhyd = IEhydt=0
n
∑          (2) 
 
The DSF value corrected for the ligand fluctuation (RMSD) with respect to the 
starting position yields the weighted DSF (wDSF), a number that highlights 
differences between stable and unstable poses. The corresponding weighted 
electrostatic and hydrophobic DSFs (denoted as wDSFele and DSFhyd, 
respectively) are therefore obtained as reported below: 
 
wDSFele =
IEelet=0
n
∑
RMSD          (3) 
wDSFhyd =
IEhydt=0
n
∑
RMSD          (4) 
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Figure 1. Schematic representation of the developed tools: A) Protocol Score; B) 
Interaction Energy Maps (IEMs); C) RMSD weighted Dynamic Scoring Function 
(wDSF); D) Water Fluid Dynamics (WFD) maps; E) Differential WFD maps; F) 
Ligand-receptor interaction energy landscape from supervised MD (SuMD) simulations. 
The figures were adapted from the original papers.18,21,27,35  
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The DSFs can be computed during the MD simulations or performed as 
a post-processing procedure, so that in principle any trajectory that has been 
previously produced can be re-analyzed with this approach. It can be regarded as 
an alternative to conventional scoring functions, as it is able to take into account 
both the complex flexibility in the membrane environment as well as water-
driven interactions. The resulting graphs (Figure 1C) obtained by plotting the 
DSFs against the simulation time enable a graphical comparison of the relative 
stability of docking poses. This representation can help in detecting and 
validating the feasibility of alternative binding conformations proposed by the 
docking algorithm. We have recently exploited this feature to support an 
apparently less plausible binding mode of a series of 5-alkylaminopyrazolo[4,3-
e]1,2,4-triazolo[1,5-c]pyrimidine at the hA3 AR.22 Moreover, we tested the 
applicability of our approach by taking part in the community- wide 2013 GPCR 
Dock Assessment.23 Among the proposed targets, we focused on the 
5HT2B/ergotamine complex, whose X-Ray structure has been released after the 
predictions were submitted. Therefore we tested the applicability of our tool to 
homology models of a system on which our laboratory did not hold expertise. 
We submitted several alternative ligand-protein complexes suggested by the 
docking protocol to membrane MD simulations and selected the best final poses 
according to the outcomes of the DSFs analysis. Our predictions ranked 8th 
among 254, suggesting the portability of our approach to homology models as 
well as to other GPCRs.23 
 
A Closer  Look at Water Molecules :  Water Fluid Dynamics  (WFD) Maps 
It is generally recognized that water molecules contribute to protein-
ligand binding in at least two ways: they either stabilize the complex by forming 
hydrogen bond networks,24 or are replaced by the ligand once the complex is 
formed.25,26 It is therefore crucial in a drug design process to be able to 
distinguish between water molecules that mediate protein-ligand interactions and 
those that can be targeted for being displaced. To this aim, we have very recently 
tuned a tool that inspects the time-dependent variation of fluid dynamics 
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properties of water molecules as a consequence of the binding event by means 
of MD simulations.27 Our approach detects structural water molecules inside the 
orthosteric binding site of the receptor and collects these pieces of information 
in a bi-dimensional graph, that we called water fluid dynamics (WFD) map. 
Unlike other existing MD based methodologies,28,29 our approach is aimed at 
localizing protein “hot-spots” – i.e. regions where water molecules playing a key 
role in ligand binding mostly reside – rather than estimating their binding affinity. 
The WFD maps have been therefore mainly conceived as qualitative tool to 
drive ligand design to avoid substituents disrupting key water molecules’ 
networks.  
The WFD maps are derived as follows: residues within a range of 5 Å 
from the ligand are selected and a box surrounding the binding site is created 
and split into a threedimensional grid. During the MD simulations the diffusion 
of water molecules in each grid cell is followed. The data are acquired by saving 
the MD trajectories at regular intervals (every 10 ps) and by projecting the 
averaged position of water molecules showing a RMSF value below 1.4 Å into a 
bi-dimensional grid. The overlap of these grids yields a map (Figure 1D) with cell 
colored according to the residence time of water molecules on a 0–100% scale. 
White zones (0%) are occupied by water molecules with a residence time 
equivalent to bulk, whereas blue regions (100%) are occupied by trapped water 
molecules showing the maximum residence time of the considered trajectory. 
The maps allow a fast graphical identification of water distribution inside the 
orthosteric binding pocket. Moreover, “differential” WFD maps representing by 
a color code the enrichment or displacement of water molecules as a 
consequence of ligand binding (Figure 1E) are derived by comparing the WFD 
maps of the receptor in the apo and bound states. 
 
Explor ing the Ligand-Receptor Recogni t ion Process :  the  
Supervised Molecular Dynamics  (SuMD) Approach 
One of the most challenging tasks for ligand-GPCRs modeling is the 
prediction of the recognition pathway, an event which knowledge would ease the 
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development of drug candidates with better pharmacodynamic profiles. 
Unfortunately, the recognition of a ligand by a receptor is a process hard to 
simulate as it requires classical MD experiments in a long microsecond time 
scale.14,30,31. To overcome this technical limitation, enhanced sampling methods 
that facilitate the crossing of energy barriers through the introduction of biased 
potentials have been developed.23,33. Another approach,34 induces ligand 
unbinding by applying external forces to the system, thus requiring knowledge of 
the ligand-receptor complex final state. Within this framework, we have recently 
proposed an alternative strategy – the “supervised molecular dynamics” 
(SuMD)35 – that enables to follow the ligand-GPCR approaching path by 
considerably reducing the simulation time scale and without introducing bias. 
SuMD performs standard simulations in which the distance between the center 
of masses of the ligand atoms and the receptor binding site is monitored by a 
tabu-like algorithm. If the location of the binding site is unknown, several 
simulations are run by setting the centers of previously detected cavities. An 
arbitrary number of distance points is collected “on the flight” and fitted into a 
linear function f(x)=mx. The tabu-like algorithm is applied to increase the 
probability to produce ligand-receptor binding events as follows: If the slope (m) 
is negative, the ligand-receptor distance is likely to be shortened and a classic 
MD simulation is restarted from the last set of coordinates. Otherwise, the 
simulation is restored from the original set of coordinates and random velocities 
are reassigned to each atom. The supervision is repeated until the ligand-receptor 
distance is less than 5 Å. 
The results of a SuMD simulation are displayed in a graph reporting the 
interaction energy toward the distance between the ligand and the binding site 
(Figure 1F). This approach can be exploited to analyze binding events to both 
orthosteric and allosteric sites and to assist the design of site-directed 
mutagenesis experiments in order to infer the role of specific residues on the 
molecular recognition process. 
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Application to Drug Design 
To explain the applicability of the described tools, we discuss here as case 
study the comparison between ZM 241385 and caffeine, a strong and a weak 
hA2A AR binder with pKD values 9.18.0.23 and 5.31.0.44, respectively.36 
Among the hA2A AR available crystal structures we have selected the two co-
crystallized with the ligands of interest identified by the following PDB IDs: 
3EML and 3RFM.36,37. The starting point of the study is the evaluation of the 
reproducibility of the X-Ray binding modes through docking calculations. To 
accomplish this task we compare the IEMs computed for the best performing 
docking protocols. We then proceed by evaluating the dynamic evolution of 
alternative binding modes proposed by the docking algorithm, thus imaging the 
common case where X-Ray structures are not available for comparison. As 
anticipated, MD simulations allow taking into account the flexibility of the 
receptor and the role of water molecules in the binding. A more careful 
inspection of water dynamics is then performed by deriving differential WFD 
maps from the computed trajectories of a selected docking pose for each 
structure. Finally, we move outside the receptor and try to reproduce the binding 
pathways from the extracellular side through SuMD experiments. 
 
Assess ing the Reproducibi l i ty  o f  a Binding Mode:  IEMs Comparison 
We start our case study by assessing the performance of a previously 
selected docking algorithm through IEMs inspection.18 Figure 2 displays the 
comparison between the computed IEMs for the two considered structures. As 
shown, the binding mode of ZM 241385 (3EML, Figure 2A) encompasses a 
tight interaction network that is correctly reproduced by the majority of the 20 
generated poses. On the other hand, the caffeine binding mode (3RFM, 
Figure2B) is more challenging to be reproduced and implies a lower number of 
less intense interactions with the binding site residues. The comparison of IEMs 
therefore helps evaluating in a fast graphical fashion both the docking protocol 
performances and the reproducibility of X-Ray observed binding modes. 
Interaction patterns without interruptions are clue of binding modes easy to 
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reproduce and indicate good protocol performances, whereas discontinuous 
patterns suggest binding modes challenging to be predicted and unsatisfactory 
protocol performances. 
 
Fol lowing the Dynamics  o f  Ligand-receptor  Interac t ions :wDSFs Prof i l e s  
When the X-ray structures of the ligand-protein complex of interest are 
not available, usually a modeler is asked to select among several feasible binding 
modes suggested by the docking protocol slightly differing for the assigned 
scores. How to recognize the solution best approaching the “real” binding 
mode? Figure 3 displays the exercise we have conducted to address this issue: in 
order to identify as many different as possible binding modes, we forced the 
docking protocol to return ten poses that differed in terms of RMSD for at least 
1.75 Å.27 Nevertheless, the protocol assigned to the generated conformations 
scores differing at most for ten units. We subjected each docking pose to MD 
simulation and evaluated the wDSFs. Figure 3A–B displays the results for the 
two considered structures: the different values of both the cumulative 
electrostatic and the hydrophobic contributions reflect the different affinities of 
the two binders. In particular, ZM 241385 exhibits higher absolute values for 
both contribution types consistently with its higher affinity for the receptor. 
Moreover, for both structures, the wDSFs trends enable to graphically recognize 
the pose that best reproduces the X-ray observed binding mode, i.e. the one 
showing the slope with the highest absolute value. 
 
What About the Role  o f  Water Molecules? WFD Maps Inspec t ion 
A detailed inspection of the WFD maps of the two considered 
compounds further contributes to explain their different binding affinities to the 
hA2A AR. The WFD map for the ZM 241385 complex (Figure 4A) highlights 
the presence of water molecules bridging the aromatic scaffold to key residues in 
the binding site, namely Tyr9, Glu13, His278, Asn253, and Glu169.27 The 
interactions with some of those residues were already detected from the docking 
pose, whereas other ones arose from MD simulations. The differential WFD 
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map (Figure 4B) highlights that the ligand displaces water molecules close to 
Thr88 while binding. The WFD map corresponding to the caffeine complex 
(Figure 4C), instead, shows a high propensity of bulk water molecules to solvate 
the fragment-like compound.27 This is a direct consequence of the lack of strong 
interactions with the residues of the binding site detected during the MD 
simulation and aid explaining the lower affinity of the compound. 
 
 
Figure 2. Comparison of IEMs for two hA2A AR ligands: ZM 241385 (A) and caffeine 
(B). While ZM 241385 establishes a strong interaction network conserved among the 
20 generated poses, caffeine finds lower number and less intense interactions. IEele 
values: kcal Å-1 mol-1, IEhyd values: arbitrary units. The figures were adapted from the 
original papers.18 
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On the Extrace l lu lar Side o f  hA2A AR: the SuMD Approach  
On its way to the orthosteric binding site, the ligand might interact with 
the so-called meta-binding sites,38 which in some cases, may coincide with 
possible allosteric sites. The SuMD path we have computed for ZM 241385 
highlights two major interaction sites: the second and third extracellular loop 
(EL2 and EL3, respectively, Figure 5A).35 As depicted in the diagram in Figure 
5B, although a higher interaction (less favorable) energy is associated to these 
metabinding sites, they seem to play a role in tuning the correct orientation of 
the ligand scaffold while approaching the orthosteric site. The EL3 also takes 
part in the caffeine recognition pathway (Figure 5C),35 which, however, lacks 
strong interactions with the orthosteric site (Figure 5D). The SuMD simulations 
thus recognize the critical role of the hA2A AR extracellular loops in the ligand 
recognition process, role that has been postulated in the past by using site-
directed mutagenesis.39,40 We have recently applied the SuMD approach to 
interpret the binding of two challenging ligands: (i) the natural agonist and a (ii) 
imidazoquinolinamine derivative acting as positive modulator (LUF6000). The 
binding of the natural agonist adenosine at the hA2 AR revealed a possible 
energetically stable meta-binding site.41 The SuMD simulations suggested at least 
two possible mechanisms to explain the available experimental data for the 
positive allosteric modulation mediated by LUF6000 toward the hA3 AR.42 
 
Summary and Outlook 
Through this paper, we have surveyed the recent advances carried out by 
our research groups in modeling the ligand- GPCRs recognition process. The 
crystallographic revolution of the last decade, on one side, and the advent of 
graphics processing units (GPUs) in the molecular modeling field, on the other 
side, allowed us to tune several tools to assist the drug design procedure. 
The proposed approaches enrich the pool of molecular modeling 
techniques currently available to disclose the factors influencing the ligand-
GPCRs recognition process and exploit two computational methodologies 
extensively used by modelers such as molecular docking and membrane MD 
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simulations. The majority of the methods herein presented are conceived as 
post-processing procedures, so that in principle any docking output or MD 
trajectory previously obtained can be rapidly re-analyzed using these tools. 
Moreover, the full automation of the procedures as well as the presentation of 
the results as easy to interpret colored maps are aimed at broadening their 
applicability within the scientific community encouraging non-expert users to 
approach them. A different philosophy is instead at the basis of the SuMD 
approach, which introduces a supervision of the MD trajectory through a tabu-
like algorithm to speed up the computation time required to inspect the ligand- 
GPCRs recognition event. The comparison between ZM 241385 and caffeine, a 
strong and a weak hA2A AR antagonists, has been presented as case study to 
explain the usefulness and potentiality of our approaches. 
As a future perspective we foresee to extend and improve the 
applicability of these computational tools to address other fascinating open 
questions in GPCRs field. We would like to summarize some of the hottest 
topics in the area: a) clarify at the molecular level the orthosteric and the 
allosteric control mediated by different binders on GPCR functionality; b) 
elucidate the implication of phosphorylation and glycosylation in both ligand 
binding and receptor activation; c) understanding the physio-pathological 
meaning of monomer-oligomer (homo and/or hetero) receptor equilibrium; d) 
identification of novel second messengers involved in G protein-alternative 
signaling path- ways; e) explore the possibility to perform high-throughput 
SuMD (HTSuMD) simulations for virtual screening applications as well as for 
real-time interpretations of mutagenesis data. 
Concluding, we hope that these computational approaches carefully 
integrated with all other experimental GPCRs competencies will broaden our 
perspectives in several scientific areas from molecular pharmacology to drug 
discovery.  
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Figure 3. wDSFs comparison: A) ZM 241385 wDSFhyd (top) and wDSFele (down); B) 
caffeine wDSFhyd (top) and wDSFele (down). IEele values: kcal Å-1 mol-1. IEhyd values: 
arbitrary units. For both ligands the boundle of poses subjected to MD are rendered 
coloring pose number 1 in red. The same color scheme is used in the plots to identify 
pose 1 among the others. The figures were adapted from the original paper.21 
 
Figure 4. WFD maps comparison: A) position of water molecules experimentally 
determined for ZM 241385 complex structure; B) differential WFD for ZM 241385 in 
comparison to the apo-state of hA2A AR; C) differential WFD for caffeine in 
comparison to the apo-state of hA2A AR. Receptors are viewed from the membrane side 
facing TM6 and TM7. Side chains of key residues are displayed as gray sticks. Hydrogen 
atoms are not displayed. The figures were adapted from the original paper.27 
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Figure 5. SuMD experiments on hA2A AR. Top: electrostatic and hydrophobic 
contributions to the interaction energy of each receptor residue involved in the binding 
with A) ZM 241385 and B) caffeine. Down: SuMD ligand-receptor interaction energy 
landscape for C) ZM 241385 and D) caffeine. Interaction Energy values: kcalmolÅë1. 
The figures were adapted from the original paper.35 
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The power of molecular dynamics simulation to tackle complicate SBDD 
aspects linked to the intrinsic dynamicity of macromolecular targets, ligands and 
environment at molecular level has been demonstrated in this Ph.D. thesis.  
The SuMD technique showed a broad applicability being able to 
reproduce final bound configurations in good agreement with the experimental 
X-ray crystallographic complexes for both cytosolic and membrane proteins. 
First innovative aspect of this method is the time needed for simulate the 
stochastic event represented by the ligand - protein binding: it falls in the 
nanosecond timescale, while it usually needs microseconds of non-supervised 
molecular dynamics simulation. Moreover, SuMD has the value to allow simulate 
multiple binding events, therefore to sample different putative recognition 
pathway and multiple metastable binding sites that can act as modulators of the 
overall kinetics of the binding, whose quantitative estimation should be the next 
issue addressed by means of the method.  
The importance of the metastable sites, encountered on its way to the 
orthosteric site of the A2A AR, was highlighted for the endogenous effector 
adenosine. More precisely, various protein residues locate on the EL3 and EL2 
participate to the ligand transition from the bulk solvent to the final bound state 
(in accordance with mutagenesis studies). An interesting topic outlined by the 
simulations is the adenosine difficulty to gain a stable orthosteric conformation, 
preferring to experience an ensemble of different orientations. Further 
investigations on this peculiar behaviour are ongoing, considering a recently 
disclosed X-ray crystal structure of the A2A AR bound to an engineered G 
protein[1]: the aim is to determine if an almost completely active receptor 
conformation is able to better stabilize the agonist. 
SuMD outcomes for the PAM LUF6000 on A3 AR, to the better of our 
knowledge, for the first time addresses the allosterically-enhanced agonist affinity 
with the formation of a ternary intermolecular complex, that involves protein, 
agonist and allosteric modulator. This mechanism, if further confirmed, should 
                                            
1 Carpenter B, Nehmé R, Warne T, Leslie AG, Tate CG. Structure of the adenosine 
A2A receptor bound to an engineered G protein. Nature, 536, 104–107. 
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be considered as an alternative way to mediate allosterism, beside the well 
established model that consider protein conformational changes occurring upon 
PAM binding. 
Moving to the last paper presented, the molecular dynamics’ utility in an 
integrated drug design strategy was described. Indeed, it is a useful tool for the 
quality evaluation of molecular docking results as well as a reliable method for 
discriminate strong binders from weak binders, as demonstrated by the example 
of caffeine and ZM241385 on the A2A AR. In our opinion, high throughput 
SuMD simulations should become an important part of SBDD programs. 
Finally, a SuMD-like approach combined to metadynamics is currently 
under development[2], with the aim of sampling unbinding events and to obtain 
useful insights also from ligand- receptor dissociation mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
2  Giuseppe Deganutti, Andrei Zhukov, Stephanie Federico, Giampiero Spalluto, 
Stefano Moro, Jonathan S. Mason and Andrea Bortolato. Identification of Putative 
Adenosine A2A Ligand Binding Kinetics Bottlenecks Explain Their Transition State 
Thermodynamics Properties. Manuscript in preparation. 
 
